Document:

Exhibit 10.2

 

SUBSCRIPTION AGREEMENT

 

InterPrivate Acquisition Corp.

1350 Avenue of the Americas

New York, NY 10019

 

Ladies and Gentlemen:

 

In connection with
the proposed business combination (the “Transaction”) between InterPrivate Acquisition Corp., a Delaware corporation
(the “Company”), and Aeva, Inc., a Delaware corporation (“Aeva”), the undersigned desires
to subscribe for and purchase from the Company, and the Company desires to sell to the undersigned, that number of shares of the
Company’s common stock, par value $0.0001 per share (the “Common Stock”), set forth on the signature page
hereof for a purchase price of $10.00 per share (the “Per Share Price” and the aggregate of such Per Share Price
for all Shares subscribed for by the undersigned being referred to herein as the “Purchase Price”), on the terms
and subject to the conditions contained herein. In connection with the Transaction, certain other institutional “accredited
investors” (as defined in rule 501 under the Securities Act of 1933, as amended (the “Securities Act”))
have entered into separate subscription agreements with the Company (the “Other Subscription Agreements”), pursuant
to which such investors (the “Other Subscribers”) have, together with the undersigned pursuant to this Subscription
Agreement, agreed to purchase an aggregate of [                    
] shares of Common Stock at the Per Share Price (the undersigned being referred to sometimes herein as the “Subscriber”).  In
connection therewith, the undersigned and the Company agree as follows:

 

1. Subscription.
Subject to the provisions of Section 2 hereof, the undersigned hereby irrevocably subscribes for and agrees to purchase from the
Company such number of shares of Common Stock as is set forth on the signature page of this Subscription Agreement on the terms
and subject to the conditions provided for herein (the “Shares”). The undersigned understands and agrees that
the undersigned’s subscription for the Shares shall be deemed to be accepted by the Company if and when this Subscription
Agreement is signed and delivered by a duly authorized person by or on behalf of the Company; the Company may do so in counterpart
form. In the event of rejection of a portion of the subscription by the Company, a portion of the undersigned’s payment hereunder,
if any, in an amount equal to the portion of the subscription so rejected will be returned promptly (but not later than one (1) business
day thereafter) to the undersigned. In the event of rejection of the entire subscription by the Company in accordance with the
terms hereof, the undersigned’s payment hereunder, if any, will be returned promptly (but not later than one (1) business
day thereafter) to the undersigned along with this Subscription Agreement, and this Subscription Agreement thereafter shall have
no force or effect.

 

For the purposes of
this Subscription Agreement, “business day” means any other day than a Saturday, Sunday or a day on which the
Federal Reserve Bank of New York is closed.

 

     

     

    

 

2. Closing.
The closing of the sale of the Shares contemplated hereby (the “Subscription Closing”) is contingent upon the
substantially concurrent consummation of the Transaction (the “Transaction Closing”). The Subscription Closing
shall occur on the date of, and immediately prior to, the consummation of the Transaction (the “Transaction Closing Date”).
Not less than ten (10) business days prior to the scheduled Transaction Closing Date, the Company shall provide written notice
to the undersigned (the “Closing Notice”) (i) of such scheduled Transaction Closing Date, (ii) that the Company
reasonably expects all conditions to the closing of the Transaction to be satisfied or waived, and (iii) wire instructions for
delivery of the Purchase Price to the Escrow Agent (as defined below). The undersigned shall deliver to Continental Stock Transfer
& Trust Company, as escrow agent (the “Escrow Agent”), at least two (2) business days prior to the Transaction
Closing Date specified in the Closing Notice, the Purchase Price, which shall be held in a segregated escrow account for the benefit
of the Subscriber (the “Escrow Account”) until the Subscription Closing pursuant to the terms of a customary
escrow agreement, which shall be on terms and conditions reasonably satisfactory to the undersigned to be entered into by the Company
and the Escrow Agent (the “Escrow Agreement”), by wire transfer of United States dollars in immediately available funds
to the account specified by the Company in the Closing Notice. The Company shall provide to the undersigned, no later than the
date on which the Closing Notice is delivered to the undersigned, a copy of the executed Escrow Agreement to be in force on the
Transaction Closing Date. On the Transaction Closing Date, the Company shall deliver to the undersigned (i) the Shares in book-entry
form, or, if required by the undersigned, certificated form, free and clear of any liens or other restrictions whatsoever (other
than those arising under state or federal securities laws as set forth herein), in the name of the undersigned (or its nominee
in accordance with its delivery instructions) or to a custodian designated by the undersigned, as applicable, and (ii) a copy
of the records of the Company’s transfer agent showing the undersigned (or such nominee or custodian) as the owner of the
Shares on and as of the Transaction Closing Date. Upon delivery of the Shares to the undersigned (or its nominee or custodian,
if applicable), the Purchase Price shall be released from the Escrow Account automatically and without further action by the Company
or the undersigned.

 

If the Transaction
Closing does not occur within two (2) business days after the Transaction Closing Date specified in the Closing Notice, the Escrow
Agent shall promptly (but not later than one (1) business day thereafter) return the Purchase Price to the undersigned by
wire transfer of U.S. dollars in immediately available funds to the account specified by the undersigned. Furthermore, if the Transaction
Closing does not occur on the same day as the Subscription Closing, the Escrow Agent (or the Company, if the Purchase Price has
been released by the Escrow Agent) shall promptly (but not later than one (1) business day thereafter) return the Purchase
Price to the undersigned by wire transfer of U.S. dollars in immediately available funds to the account specified by the undersigned,
and any book-entries and, if applicable, certificated shares, shall be deemed cancelled (and, in the case of certificated shares,
the undersigned shall promptly return such certificates to the Company or, as directed by the Company, to the Company’s representative
or agent).

 

If this Subscription
Agreement terminates following the delivery by the undersigned of the Purchase Price for the Shares, the Escrow Agent shall promptly
(but not later than one (1) business day thereafter) return the Purchase Price to the undersigned, whether or not the Transaction
Closing shall have occurred. If this Subscription Agreement terminates following the Transaction Closing, the undersigned shall
promptly upon the return to the undersigned of the Purchase Price by the Escrow Agent, transfer the Shares to the Company.

 

    2

     

    

 

3. Closing Conditions.

 

a. The obligations of
the Company to consummate the transactions contemplated hereunder are subject to the conditions that, at the Subscription Closing:

 

		i.	all representations and warranties of the undersigned contained in this Subscription Agreement
shall be true and correct in all material respects (other than representations and warranties that are qualified as to materiality,
which representations and warranties shall be true and correct in all respects) at and as of the Subscription Closing as though
made on the Subscription Closing (except for those representations and warranties that speak as of a specific date, which shall
be so true and correct in all material respects as of such specified date), and consummation of the Subscription Closing shall
constitute a reaffirmation by the undersigned of each of the representations, warranties and agreements of the undersigned contained
in this Subscription Agreement as of the Subscription Closing, but in each case without giving effect to consummation of the Transaction;
and

 

		ii.	the undersigned shall have performed or complied in all material respects with all agreements and
covenants required by this Subscription Agreement.

 

b. The obligations of
the undersigned to consummate the transactions contemplated hereunder are subject to the conditions that, at the Subscription Closing:

 

		i.	all representations and warranties of the Company contained in this Subscription Agreement shall
be true and correct in all material respects (other than representations and warranties that are qualified as to materiality or
Material Adverse Effect (as defined herein), which representations and warranties shall be true and correct in all respects) at
and as of the Subscription Closing as though made on the Subscription Closing (except for those representations and warranties
that speak as of a specific date, which shall be so true and correct in all material respects as of such specified date), and consummation
of the Subscription Closing shall constitute a reaffirmation by the Company of each of the representations, warranties and agreements
of the Company contained in this Subscription Agreement as of the Subscription Closing, but in each case without giving effect
to consummation of the Transaction;

 

		ii.	the Company shall have performed or complied in all material respects with all agreements and covenants
required by this Subscription Agreement; and

 

		iii.	no amendment, modification or waiver of the Transaction Agreement (as defined below) shall have
occurred that reasonably would be expected to materially and adversely affect the economic benefits that the Subscriber reasonably
would expect to receive under this Subscription Agreement.

 

    3

     

    

 

c. The obligations of
each of the Company and the undersigned to consummate the transactions contemplated hereunder are subject to the conditions that,
at the Subscription Closing:

 

		i.	no governmental authority shall have enacted, issued, promulgated, enforced or entered any judgment,
order, law, rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making
consummation of the transactions contemplated hereby illegal or otherwise restraining or prohibiting consummation of the transactions
contemplated hereby, and no governmental authority shall have instituted or threatened in writing a proceeding seeking to impose
any such restraint or prohibition; and

 

		ii.	all conditions precedent to the closing of the Transaction set forth in the Transaction Agreement,
including the approval of the Company’s stockholders and regulatory approvals, if any, shall have been satisfied or waived
(other than those conditions which, by their nature, are to be satisfied by a party to the Transaction Agreement at the closing
of the Transaction, but subject to satisfaction or waiver by such party of such conditions as of the closing of the Transaction).

 

4. Further Assurances.
At the Subscription Closing, the parties hereto shall execute and deliver or cause to be executed and delivered such additional
documents and take such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate
the subscription as contemplated by this Subscription Agreement.

 

5. Company Representations
and Warranties. The Company represents and warrants to the undersigned that

 

a. The Company is validly
existing and is in good standing under the laws of the State of Delaware, with corporate power and authority to own, lease and
operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under
this Subscription Agreement.

 

b. The Shares have been
duly authorized and, when issued and delivered to the undersigned against full payment therefor in accordance with the terms of
this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable and will not have been issued in
violation of or subject to any preemptive or similar rights created under the Company’s Amended and Restated Certificate
of Incorporation or under the laws of the State of Delaware.

 

c. The authorized capital stock of the Company
consists of (i) 1,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”) and (ii)
50,000,000 shares of Common Stock. As of the date hereof and as of immediately prior to the Subscription Closing and the Transaction
Closing: (A) no shares of Preferred Stock are issued and outstanding and (B) 31,055,500 shares of Common Stock are issued and outstanding.

 

    4

     

    

 

d. The Shares are not,
and following the Transaction Closing and the Subscription Closing will not be, subject to any Transfer Restriction. The term “Transfer
Restriction” means any condition to or restriction on the ability of the undersigned to pledge, sell, assign or otherwise
transfer the Shares under any organizational document, policy or agreement of, by or with the Company, but excluding the restrictions
on transfer described in paragraph 6(c) of this Subscription Agreement with respect to the status of the Shares as “restricted
securities” pending their registration for resale under the Securities Act in accordance with the terms of this Subscription
Agreement.

 

e. This Subscription
Agreement has been duly authorized, executed and delivered by the Company and is enforceable in accordance with its terms, except
as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other
laws relating to or affecting the rights of creditors generally, and (ii) principles of equity, whether considered at law or equity.

 

f. The issuance and sale
of the Shares and the compliance by the Company with all of the provisions of this Subscription Agreement and the consummation
of the transactions herein will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute
a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets
of the Company or any of its subsidiaries pursuant to the terms of (i) any indenture, mortgage, deed of trust, loan agreement,
lease, license or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company
or any of its subsidiaries is bound or to which any of the property or assets of the Company is subject, which would reasonably
be expected to have a material adverse effect on the business, properties, financial condition, stockholders’ equity or results
of operations of the Company (a “Material Adverse Effect”) or materially affect the validity of the Shares or
the legal authority of the Company to comply in all material respects with the terms of this Subscription Agreement; (ii) result
in any violation of the provisions of the organizational documents of the Company; or (iii) result in any violation of any statute
or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction
over the Company or any of its properties that would reasonably be expected to have a Material Adverse Effect or materially affect
the validity of the Shares or the legal authority of the Company to comply with this Subscription Agreement.

 

g. The Company is not
required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with,
any court or other federal, state, local or other governmental authority, self-regulatory organization (including The New York
Stock Exchange (“NYSE”)) or other person in connection with the execution, delivery and performance of this
Subscription Agreement (including, without limitation, the issuance of the Shares), other than (i) filings with the Securities
and Exchange Commission (the “Commission”), (ii) filings required by applicable state securities laws, (iii)
filings required by NYSE, including with respect to obtaining shareholder approval, (iv) filings required to consummate the Transaction
as provided under the definitive documents relating to the Transaction, and (v) where the failure of which to obtain would not
be reasonably likely to have a Material Adverse Effect or have a material adverse effect on the Company’s ability to consummate
the transactions contemplated hereby, including the issuance and sale of the Shares.

 

    5

     

    

 

h. The Company has not
received any written communication from a governmental entity that alleges that the Company is not in compliance with or is in
default or violation of any applicable law, except where such non-compliance, default or violation would not be reasonably likely
to have, individually or in the aggregate, a Material Adverse Effect.

 

i. The issued and outstanding
shares of Common Stock of the Company are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and are listed for trading on NYSE under the symbol “IPV” (it being
understood that the trading symbol will be changed in connection with the Transaction Closing). Except as disclosed in the Company’s
filings with the Commission, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company,
threatened against the Company by NYSE or the Commission, respectively, to prohibit or terminate the listing of the Company’s
Common Stock on NYSE or to deregister the Common Stock under the Exchange Act. The Company has taken no action that is designed
to terminate the registration of the Common Stock under the Exchange Act.

 

j. Assuming the accuracy
of the undersigned’s representations and warranties set forth in Section 6 of this Subscription Agreement, no registration
under the Securities Act is required for the offer and sale of the Shares by the Company to the undersigned.

 

k. A copy of each form,
report, statement, schedule, prospectus, proxy, registration statement and other document, if any, filed by the Company with the
Commission since its initial registration of the Common Stock under the Exchange Act (the “SEC Documents”) is
available to the undersigned via the Commission’s EDGAR system. None of the SEC Documents contained, when filed or, if amended,
as of the date of such amendment with respect to those disclosures that are amended, any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, that with respect to the information about the Company’s
affiliates contained in the Schedule 14A and related proxy materials (or other SEC document) to be filed by the Company the representation
and warranty in this sentence is made to the Company’s knowledge. The Company has timely filed each report, statement, schedule,
prospectus, and registration statement that the Company was required to file with the Commission since its initial registration
of the Common Stock under the Exchange Act. There are no material outstanding or unresolved comments in comment letters from the
staff of the Division of Corporation Finance (the “Staff”) of the Commission with respect to any of the SEC
Documents.

 

l. Except for such matters
as have not had and would not be reasonably likely to have, individually or in the aggregate, a Material Adverse Effect, there
is no (i) action, suit, claim or other proceeding, in each case by or before any governmental authority pending, or, to the knowledge
of the Company, threatened against the Company or (ii) judgment, decree, injunction, ruling or order of any governmental entity
or arbitrator outstanding against the Company.

 

m. Other than the Other
Subscription Agreements, the Company has not entered into any side letter or similar agreement with any Other Subscriber in connection
with such Other Subscriber’s direct or indirect investment in the Company or with any other investor, and such Other Subscription
Agreements have not been amended in any material respect following the date of this Subscription Agreement and reflect the same
Per Share Purchase Price and terms that are not materially more favorable to such Other Subscriber thereunder than the terms of
this Subscription Agreement.

 

    6

     

    

 

n. The Company acknowledges
and agrees that, notwithstanding anything herein to the contrary, the Shares may be pledged by the Subscriber in connection with
a bona fide margin agreement, which shall not be deemed to be a transfer, sale or assignment of the Shares hereunder, and the Subscriber
effecting a pledge of Shares shall not be required to provide the Company with any notice thereof or otherwise make any delivery
to the Company pursuant to this Subscription Agreement; provided that such pledge shall be (i) pursuant to an available exemption
from the registration requirements of the Securities Act or (ii) pursuant to, and in accordance with, a registration statement
that is effective under the Securities Act at the time of such pledge. The Company hereby agrees to execute and deliver such documentation
as a pledgee of the Shares may reasonably request in connection with a pledge of the Shares to such pledgee by the Subscriber,
provided that the Subscriber shall be responsible for payment of legal fees and expenses incurred by the Company in connection
with such request.

 

6. Subscriber Representations
and Warranties. The undersigned represents and warrants to the Company that:

 

a. The undersigned is
(i) a “qualified institutional buyer” (as defined under the Securities Act) or (ii) an institutional “accredited
investor” (within the meaning of Rule 501(a) under the Securities Act), in each case, satisfying the requirements set forth
on Schedule A, and is acquiring the Shares only for his, her or its own account and not for the account of others, and not
on behalf of any other account or person or with a view to, or for offer or sale in connection with, any distribution thereof in
violation of the Securities Act (and shall provide the requested information on Schedule A following the signature page
hereto). Accordingly, the undersigned understands that the offering of the Shares meets the exemptions from filing under FINRA
Rule 5123(b)(1)(C) or (J).

 

b. The undersigned (i)
is an institutional account as defined in FINRA Rule 4512(c), (ii) is a sophisticated investor, experienced in investing in private
equity transactions and capable of evaluating investment risks independently, both in general and with regard to all transactions
and investment strategies involving a security or securities and (iii) has exercised independent judgment in evaluating its participation
in the purchase of the Shares. Accordingly, the undersigned understands that the offering of the Shares meets (x) the exemptions
from filing under FINRA Rule 5123(b)(1)(A) and (y) the institutional customer exemption under FINRA Rule 2111(b).

 

    7

     

    

 

c. The undersigned understands
that the Shares are being offered in a transaction not involving any public offering within the meaning of the Securities Act and
that the Shares have not been registered under the Securities Act. The undersigned understands that the Shares may not be resold,
transferred, pledged or otherwise disposed of by the undersigned absent an effective registration statement under the Securities
Act except (i) to the Company or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur outside
the United States within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable exemption
from the registration requirements of the Securities Act, and in each of cases (i) and (iii) in accordance with any applicable
securities laws of the states and other jurisdictions of the United States, and that any certificates or book-entry positions representing
the Shares shall contain a legend to such effect. The undersigned acknowledges that the Shares will not be immediately eligible
for resale pursuant to Rule 144 promulgated under the Securities Act and, as a result, the undersigned may not be able to readily
resell the Shares and may be required to bear the financial risk of an investment in the Shares for an indefinite period of time.
The undersigned understands that it has been advised to consult legal counsel prior to making any offer, resale, pledge or transfer
of any of the Shares.

 

d. The undersigned understands
and agrees that the undersigned is purchasing Shares directly from the Company. The undersigned further acknowledges that there
have been no representations, warranties, covenants and agreements made to the undersigned by the Company, its officers or directors,
or any other party to the Transaction or person or entity, expressly or by implication, other than those representations, warranties,
covenants and agreements included in this Subscription Agreement.

 

e. Either (i) the undersigned
is not a Benefit Plan Investor as contemplated by the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
or (ii) the undersigned’s acquisition and holding of the Shares will not constitute or result in a non-exempt prohibited
transaction under Section 406 of ERISA, Section 4975 of the Internal Revenue Code of 1986, as amended, or any applicable similar
law.

 

f. The undersigned acknowledges
and agrees that the undersigned has received and has had an adequate opportunity to review, such financial and other information
as the undersigned deems necessary in order to make an investment decision with respect to the Shares and made its own assessment
and is satisfied concerning the relevant tax and other economic considerations relevant to the undersigned’s investment in
the Shares. Without limiting the generality of the foregoing, the undersigned acknowledges that it has reviewed the documents provided
to the undersigned by the Company. The undersigned represents and agrees that the undersigned and the undersigned’s professional
advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information as the
undersigned and such undersigned’s professional advisor(s), if any, have deemed necessary to make an investment decision
with respect to the Shares. The undersigned further acknowledges that the information provided to the undersigned is preliminary
and subject to change and the Company is under no obligation to inform the undersigned regarding any such changes, except to the
extent such changes would reasonably be expected to cause the failure of the Company to satisfy a condition to the Subscriber’s
obligations at the Closing set forth in Section 3(b).

 

g. The undersigned became
aware of this offering of the Shares solely by means of direct contact between the undersigned and the Company or a representative
of the Company, and the Shares were offered to the undersigned solely by direct contact between the undersigned and the Company
or a representative of the Company. The undersigned did not become aware of this offering of the Shares, nor were the Shares offered
to the undersigned, by any other means. The undersigned acknowledges that the Company represents and warrants that the Shares (i)
were not offered by any form of general solicitation or general advertising and (ii) are not being offered in a manner involving
a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws.

 

    8

     

    

 

h. The undersigned acknowledges
that it is aware that there are substantial risks incident to the purchase and ownership of the Shares. The undersigned is able
to fend for himself, herself or itself in the transactions completed herein, has such knowledge and experience in financial and
business matters as to be capable of evaluating the merits and risks of an investment in the Shares and has the ability to bear
the economic risks of such investment in the Shares and can afford a complete loss of such investment. The undersigned has sought
such accounting, legal and tax advice as the undersigned has considered necessary to make an informed investment decision.

 

i. Alone, or together
with any professional advisor(s), the undersigned has adequately analyzed and fully considered the risks of an investment in the
Shares and determined that the Shares are a suitable investment for the undersigned and that the undersigned is able at this time
and in the foreseeable future to bear the economic risk of a total loss of the undersigned’s investment in the Company. The
undersigned acknowledges specifically that a possibility of total loss exists.

 

j. In making its decision
to purchase the Shares, the undersigned has relied solely upon independent investigation made by the undersigned and the representations,
warranties and covenants contained herein. Without limiting the generality of the foregoing, the undersigned has not relied on
any statements or other information provided by the Placement Agents (as defined below) concerning the Company or the Shares or
the offer and sale of the Shares.

 

k. The undersigned understands
and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares or made any findings
or determination as to the fairness of this investment.

 

l. The undersigned is
validly existing in good standing under the laws of its jurisdiction of incorporation or formation.

 

m. The execution, delivery
and performance by the undersigned of this Subscription Agreement are within the powers of the undersigned, have been duly authorized
and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation of any court or
other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to which the undersigned is
a party or by which the undersigned is bound, and, if the undersigned is not an individual, will not violate any provisions of
the undersigned’s charter documents, including, without limitation, its incorporation or formation papers, bylaws, indenture
of trust or partnership or operating agreement, as may be applicable. The signature on this Subscription Agreement is genuine,
and the signatory, if the undersigned is an individual, has legal competence and capacity to execute the same or, if the undersigned
is not an individual, the signatory has been duly authorized to execute the same, and this Subscription Agreement constitutes a
legal, valid and binding obligation of the undersigned, enforceable against the undersigned in accordance with its terms, except
as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other
laws relating to or affecting the rights of creditors generally, and (ii) principles of equity, whether considered at law or equity.

 

    9

     

    

 

n. Neither the due diligence
investigation conducted by the undersigned in connection with making its decision to acquire the Shares nor any representations
and warranties made by the undersigned herein shall modify, amend or affect the undersigned’s right to rely on the truth,
accuracy and completeness of the Company’s representations and warranties contained herein.

 

o. The undersigned is
not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by the U.S. Treasury
Department’s Office of Foreign Assets Control (“OFAC”) or in any Executive Order issued by the President
of the United States and administered by OFAC (“OFAC List”), or a person or entity prohibited by any OFAC sanctions
program, (ii) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515, or (iii) a non-U.S.
shell bank or providing banking services indirectly to a non-U.S. shell bank. The undersigned agrees to provide law enforcement
agencies, if requested thereby, such records as required by applicable law, provided that the undersigned is permitted to do so
under applicable law. If the undersigned is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et
seq.), as amended by the USA PATRIOT Act of 2001, and its implementing regulations (collectively, the “BSA/PATRIOT Act”),
the undersigned maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT
Act. To the extent required, it maintains policies and procedures reasonably designed for the screening of its investors against
the OFAC sanctions programs, including the OFAC List. To the extent required, it maintains policies and procedures reasonably designed
to ensure that the funds held by the undersigned and used to purchase the Shares were legally derived.

 

p. No disclosure or offering
document has been prepared by Morgan Stanley & Co. LLC or Credit Suisse Securities (USA) LLC (collectively, the “Placement
Agents”) or any of their respective affiliates in connection with the offer and sale of the Shares.

 

q. The Placement Agents
and their respective directors, officers, employees, representatives and controlling persons have made no independent investigation
with respect to the Company or the Shares or the accuracy, completeness or adequacy of any information supplied to the undersigned
by the Company.

 

r. In connection with
the issue and purchase of the Shares, the Placement Agents have not acted as the undersigned’s financial advisor or fiduciary.

 

s. If the undersigned
is a resident of Canada, the undersigned hereby declares, represents, warrants and agrees as set forth in the attached Schedule
B.

 

    10

     

    

 

7. Registration
Rights.

 

a. In the event that
the Shares are not registered in connection with the consummation of the Transaction, the Company agrees that, within thirty (30)
calendar days after the consummation of the Transaction (the “Filing Deadline”), the Company will file with
the Commission (at the Company’s sole cost and expense) a registration statement (the “Registration Statement”)
registering the resale of the Shares, and the Company shall use its commercially reasonable efforts to have the Registration Statement
declared effective as soon as practicable after the filing thereof, but no later than the 60th calendar day (or 120th
calendar day if the Commission notifies the Company that it will “review” the Registration Statement) following the
Filing Deadline (such date, the “Effectiveness Date”); provided, however, that the Company’s
obligations to include the Shares in the Registration Statement are contingent upon the undersigned furnishing in writing to the
Company such information regarding the undersigned, the securities of the Company held by the undersigned and the intended method
of disposition of the Shares as shall be reasonably requested by the Company to effect the registration of the Shares, and shall
execute such documents in connection with such registration as the Company may reasonably request that are customary of a selling
stockholder in similar situations. Notwithstanding the foregoing, if the Commission prevents the Company from including in the
Registration Statement any or all of the Shares due to limitations on the use of Rule 415 of the Securities Act for the resale
of the Shares by the applicable stockholders or otherwise, the Registration Statement shall register for resale such number of
Shares which is equal to the maximum number of Shares as is permitted by the Commission. In such event, the number of Shares to
be registered for each selling stockholder named in the Registration Statement shall be reduced pro rata among all such selling
stockholders. If the Commission requests that the undersigned be identified as a statutory underwriter in the Registration Statement,
the undersigned will have an opportunity to withdraw from the Registration Statement. The Company will use its commercially reasonable
efforts to maintain the continuous effectiveness of the Registration Statement until the earliest of (i) the date on which the
Shares may be resold without volume or manner of sale limitations pursuant to Rule 144 promulgated under the Securities Act, (ii)
the date on which such Shares have actually been sold and (iii) the date which is two years after the Subscription Closing. For
purposes of clarification, any failure by the Company to file the Registration Statement by the Filing Deadline or to effect such
Registration Statement by the Effectiveness Date shall not otherwise relieve the Company of its obligations to file or effect the
Registration Statement set forth in this Section 7.

 

    11

     

    

 

b. Notwithstanding
anything to the contrary in this Subscription Agreement, the Company shall be entitled to delay or postpone the effectiveness of
the Registration Statement, and from time to time to require the Subscriber not to sell under the Registration Statement or to
suspend the effectiveness thereof, if the negotiation or consummation of a transaction by the Company or its subsidiaries is pending
or an event has occurred, which negotiation, consummation or event, the Company’s board of directors reasonably believes,
upon the advice of legal counsel, would require additional disclosure by the Company in the Registration Statement of material
information that the Company has a bona fide business purpose for keeping confidential and the non-disclosure of which in the Registration
Statement would be expected, in the reasonable determination of the Company’s board of directors, upon the advice of legal
counsel, to cause the Registration Statement to fail to comply with applicable disclosure requirements (each such circumstance,
a “Suspension Event”); provided, however, that the Company may not delay or suspend the Registration Statement
on more than three occasions or for more than sixty (60) consecutive calendar days, or more than one hundred and twenty (120) total
calendar days, in each case during any twelve-month period. Upon receipt of any written notice from the Company of the happening
of any Suspension Event (which notice shall not contain material non-public information) during the period that the Registration
Statement is effective or if as a result of a Suspension Event the Registration Statement or related prospectus contains any untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made (in the case of the prospectus) not misleading, the Subscriber
agrees that (i) it will immediately discontinue offers and sales of the Shares under the Registration Statement (excluding, for
the avoidance of doubt, sales conducted pursuant to Rule 144) until the Subscriber receives copies of a supplemental or amended
prospectus (which the Company agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and
receives notice that any post-effective amendment has become effective or unless otherwise notified by the Company that it may
resume such offers and sales, and (ii) it will maintain the confidentiality of any information included in such written notice
delivered by the Company unless otherwise required by law or subpoena. If so directed by the Company, the Subscriber will deliver
to the Company or, in the Subscriber’s sole discretion destroy, all copies of the prospectus covering the Shares in the Subscriber’s
possession; provided, however, that this obligation to deliver or destroy all copies of the prospectus covering the Shares shall
not apply (i) to the extent the Subscriber is required to retain a copy of such prospectus (a) in order to comply with applicable
legal, regulatory, self-regulatory or professional requirements or (b) in accordance with a bona fide pre-existing document retention
policy or (ii) to copies stored electronically on archival servers as a result of automatic data back-up.

 

c. The Subscriber may
deliver written notice (an “Opt-Out Notice”) to the Company requesting that the Subscriber not receive notices
from the Company otherwise required by this Section 7; provided, however, that the Subscriber may later revoke
any such Opt-Out Notice in writing. Following receipt of an Opt-Out Notice from the Subscriber (unless subsequently revoked), (i)
the Company shall not deliver any such notices to the Subscriber and the Subscriber shall no longer be entitled to the rights associated
with any such notice and (ii) each time prior to the Subscriber’s intended use of an effective Registration Statement, the
Subscriber will notify the Company in writing at least two (2) business days in advance of such intended use, and if a notice of
a Suspension Event was previously delivered (or would have been delivered but for the provisions of this Section 7(c)) and the
related suspension period remains in effect, the Company will so notify the Subscriber, within one (1) business day of the Subscriber’s
notification to the Company, by delivering to the Subscriber a copy of such previous notice of Suspension Event, and thereafter
will provide the Subscriber with the related notice of the conclusion of such Suspension Event immediately upon its availability.

 

    12

     

    

 

d. The Company shall,
notwithstanding any termination of this Subscription Agreement, indemnify, defend and hold harmless the Subscriber (to the extent
a seller under the Registration Statement), the officers, directors and agents of each of them, and each person who controls the
Subscriber (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) to the fullest
extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without
limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, that arise
out of or are based upon (i) any untrue or alleged untrue statement of a material fact contained in the Registration Statement,
any prospectus included in the Registration Statement or any form of prospectus or in any amendment or supplement thereto or in
any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required
to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement
thereto, in light of the circumstances under which they were made) not misleading, or (ii) any violation or alleged violation
by the Company of the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder, in connection
with the performance of its obligations under this Section 7, except to the extent, but only to the extent, that such untrue
statements, alleged untrue statements, omissions or alleged omissions are based upon information regarding the Subscriber furnished
in writing to the Company by the Subscriber expressly for use therein or the Subscriber has omitted a material fact from such information
or otherwise violated the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder; provided,
however, that the indemnification contained in this Section 7 shall not apply to amounts paid in settlement of any Losses if such
settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed),
nor shall the Company be liable for any Losses to the extent they arise out of or are based upon a violation which occurs (A) in
reliance upon and in conformity with written information furnished by a Subscriber, (B) in connection with any failure of such
person to deliver or cause to be delivered a prospectus made available by the Company in a timely manner, (C) as a result of offers
or sales effected by or on behalf of any person by means of a freewriting prospectus (as defined in Rule 405) that was not authorized
in writing by the Company, or (D) in connection with any offers or sales effected by or on behalf of a Subscriber in violation
of Section 7(c) hereof. The Company shall notify the Subscriber promptly of the institution, threat or assertion of any proceeding
arising from or in connection with the transactions contemplated by this Section 7 of which the Company is aware. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of an indemnified party and shall survive
the transfer of the Shares by the Subscriber.

 

e. The Subscriber shall,
severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, and each person
who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act),
to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or are based upon any
untrue or alleged untrue statement of a material fact contained in any Registration Statement, any prospectus included in the Registration
Statement, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out
of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of any prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which
they were made) not misleading to the extent, but only to the extent, that such untrue statements or omissions are based upon information
regarding the Subscriber furnished in writing to the Company by the Subscriber expressly for use therein; provided, however, that
the indemnification contained in this Section 7 shall not apply to amounts paid in settlement of any Losses if such settlement
is effected without the consent of the Subscriber (which consent shall not be unreasonably withheld, conditioned or delayed). In
no event shall the liability of any Subscriber be greater in amount than the dollar amount of the net proceeds received by the
Subscriber upon the sale of the Shares giving rise to such indemnification obligation. The Subscriber shall notify the Company
promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated
by this Section 7 of which the Subscriber is aware. Such indemnity shall remain in full force and effect regardless of any
investigation made by or on behalf of an indemnified party and shall survive the transfer of the Shares by the Subscriber.

 

    13

     

    

 

8. Termination.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the
parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest
to occur of (a) such time as the Company notifies the undersigned in writing, or publicly discloses, that it does not intend
to consummate the Transaction, (b) following the execution of a definitive agreement among the Company and Aeva with respect to
the Transaction (a “Transaction Agreement”), such date and time as such Transaction Agreement is terminated
in accordance with its terms without the Transaction being consummated, (c) upon the mutual written agreement of each of the
parties hereto to terminate this Subscription Agreement, (d) if any of the conditions to the Subscription Closing set forth
in Section 3 of this Subscription Agreement are not satisfied or waived on or prior to the Subscription Closing and, as a
result thereof, the transactions contemplated by this Subscription Agreement are not consummated at the Subscription Closing, or
(e) if the consummation of the Transaction shall not have occurred by the earlier of (x) the 10th business day after the anticipated
Transaction Closing Date specified in the Closing Notice, or (y) March 31, 2021; provided that nothing herein will
relieve any party from liability for any willful breach hereof prior to the time of termination, and each party will be entitled
to any remedies at law or in equity to recover losses, liabilities or damages arising from such breach. The Company shall promptly
notify the undersigned of the termination of the Transaction Agreement after the termination of such agreement.

 

9. Trust Account
Waiver. The undersigned acknowledges that the Company is a blank check company with the powers and privileges to effect a merger,
asset acquisition, reorganization or similar business combination involving the Company and one or more businesses or assets. The
undersigned further acknowledges that, as described in the Company’s prospectus relating to its initial public offering dated
February 3, 2020 available at www.sec.gov, substantially all of the Company’s assets consist of the cash proceeds of the
Company’s initial public offering and private placements of its securities, and substantially all of those proceeds have
been deposited in a trust account (the “Trust Account”) for the benefit of the Company, its public stockholders
and the underwriters of the Company’s initial public offering. For and in consideration of the Company entering into this
Subscription Agreement, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably waives
any and all right, title and interest, or any claim of any kind it has or may have in the future, in or to any monies held in the
Trust Account, and agrees not to seek recourse against the Trust Account, in each case, as a result of, or arising out of, this
Subscription Agreement; provided that nothing in this Section 9 shall be deemed to limit the undersigned’s right,
title, interest or claim to the Trust Account by virtue of the undersigned’s record or beneficial ownership of securities
of the Company acquired by any means other than pursuant to this Subscription Agreement.

 

10. No Short Sales.
The undersigned hereby agrees that, from the date of this Agreement until the Subscription Closing, none of the undersigned, its
controlled affiliates, or any person or entity acting on behalf of the undersigned or any of its controlled affiliates or pursuant
to any understanding with the undersigned or any of its controlled affiliates will engage in any Short Sales with respect to securities
of the Company. For purposes of this Section 10, “Short Sales” shall include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect
stock pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts,
options, puts, calls, swaps and similar arrangements (including on a total return basis), and sales and other transactions through
non-U.S. broker dealers or foreign regulated brokers.

 

    14

     

    

 

11. Miscellaneous.

 

a. The Company shall,
no later than 9:00 a.m., New York City time, on the first (1st) business day immediately following the date of this Subscription
Agreement, issue one or more press releases or file with the Commission a Current Report on Form 8-K (collectively, the “Disclosure
Document”) disclosing all material terms of the transactions contemplated hereby, the Transaction and any other material,
nonpublic information that the Company has provided to the undersigned at any time prior to the filing of the Disclosure Document.
From and after the issuance of the Disclosure Document, the undersigned shall not be in possession of any material, non-public
information received from the Company or any of its officers, directors or employees and the Subscriber shall no longer be subject
to any confidentiality or similar obligations under any current agreement, whether written or oral with the Company, the Placement
Agents, or any of their respective affiliates. Notwithstanding anything in this Subscription Agreement to the contrary, each party
hereto acknowledges and agrees that without the prior written consent of the other party hereto it will not publicly make reference
to such other party or any of its affiliates (i) in connection with the Transaction or this Subscription Agreement (provided that
the undersigned may disclose its entry into this Subscription Agreement and the Purchase Price) or (ii) in any promotional materials,
media, or similar circumstances, except, in each case, as required by law or regulation or at the request of the Staff or regulatory
agency or under the regulations of NYSE, including, in the case of the Company (a) as required by the federal securities law in
connection with the Registration Statement, (b) the filing of this Subscription Agreement (or a form of this Subscription Agreement)
with the Commission and (c) the filing of the Registration Statement on Form S-4 and Schedule 14A and related materials to be filed
by the Company with respect to the Transaction.

 

b. Neither this Subscription
Agreement nor any rights that may accrue to the undersigned hereunder (other than the Shares acquired hereunder, if any) may be
transferred or assigned.

 

c. The Company may request
from the undersigned such additional information as the Company may deem necessary to evaluate the eligibility of the undersigned
to acquire the Shares, and the undersigned promptly shall provide such information as may reasonably be requested, to the extent
readily available and to the extent consistent with its internal policies and procedures, provided that the Company agrees
to keep confidential any such information to the extent such information is not in the public domain, was not provided lawfully
to the Company by another source not under a duty of confidentiality and except to the extent disclosure of such information by
the Company is compelled by law, court order or a self-regulatory organization such as NYSE or FINRA or required to be included
in the Registration Statement.

 

d. The undersigned acknowledges
that the Company and the Placement Agents (pursuant to the ultimate sentence of this paragraph) and Aeva will rely on the acknowledgments,
understandings, agreements, representations and warranties contained in this Subscription Agreement. Prior to the Subscription
Closing, the undersigned agrees to notify the Company promptly if any of the acknowledgments, understandings, agreements, representations
and warranties set forth herein are no longer accurate in any material respect (other than those acknowledgments, understandings,
agreements, representations and warranties qualified by materiality, in which case the undersigned shall notify the Company if
they are no longer accurate in all respects). The undersigned agrees that the purchase by the undersigned of Shares from the Company
pursuant this Subscription Agreement will constitute a reaffirmation of the acknowledgments, understandings, agreements, representations
and warranties herein (as modified by any such notice) by the undersigned as of the Subscription Closing. The undersigned further
acknowledges and agrees that the Placement Agents are third-party beneficiaries of the representations and warranties of the undersigned
contained in Sections 6(a), 6(b), 6(c), 6(f), 6(h), 6(p), 6(q) and 6(r) of this Subscription Agreement.

 

    15

     

    

 

e. The Company is entitled
to rely upon this Subscription Agreement and is irrevocably authorized to produce this Subscription Agreement or a copy hereof
when required by law, regulatory authority or NYSE to do so in any administrative or legal proceeding or official inquiry with
respect to the matters covered hereby.

 

f. Except if required
by law or NYSE, without the prior written consent of the undersigned, the Company shall not, and shall cause its representatives,
including the Placement Agents and their respective representatives, not to, disclose the existence of this Subscription Agreement
or any negotiations related hereto, or to use the name of the undersigned or any information provided by the undersigned in connection
herewith in or for the purpose of any marketing activities or materials or for any similar or related purpose.

 

g. All the agreements,
representations and warranties made by each party hereto in this Subscription Agreement shall survive the Subscription Closing.

 

h. This Subscription
Agreement may not be modified, waived or terminated except by an instrument in writing, signed by the party against whom enforcement
of such modification, waiver, or termination is sought.

 

i. This Subscription
Agreement constitutes the entire agreement, and supersedes all other prior agreements, understandings, representations and warranties,
both written and oral, among the parties, with respect to the subject matter hereof. Except as otherwise expressly set forth in
subsection (d) of this Section 11, this Subscription Agreement shall not confer any rights or remedies upon any person other than
the parties hereto, and their respective successor and assigns.

 

j. Except as otherwise
provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto and their heirs,
executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties,
covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors, administrators,
successors, legal representatives and permitted assigns.

 

k. If any provision of
this Subscription Agreement shall be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining
provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and shall continue in full force
and effect.

 

    16

     

    

 

l. This Subscription
Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf) and by different parties
in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed
and delivered shall be construed together and shall constitute one and the same agreement.

 

m. The parties hereto
agree that irreparable damage would occur in the event that any of the provisions of this Subscription Agreement were not performed
in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled
to an injunction or injunctions to prevent breaches of this Subscription Agreement and to enforce specifically the terms and provisions
of this Subscription Agreement, this being in addition to any other remedy to which such party is entitled at law, in equity, in
contract, in tort or otherwise.

 

n. Notices. Any
notice or communication required or permitted hereunder shall be in writing and either delivered personally, emailed or telecopied,
sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be
deemed to be given and received (a) when so delivered personally, (b) upon receipt of an appropriate electronic answerback or confirmation
when so delivered by telecopy (to such number specified below or another number or numbers as such person may subsequently designate
by notice given hereunder), (c) when sent, with no mail undeliverable or other rejection notice, if sent by email, or (d) five
(5) business days after the date of mailing to the address below or to such other address or addresses as such person may hereafter
designate by notice given hereunder:

 

		i.	if to the undersigned, to such address or addresses set forth on the undersigned’s signature
page hereto;

 

		ii.	if to the Company, to:

 

InterPrivate Acquisition Corp.

1350 Avenue of the Americas

New York, NY 10019

Attention: Ahmed M. Fattouh; Brandon
Bentley

Email: afattouh@interprivate.com; bbentley@interprivate.com

 

with a required copy to (which copy shall not constitute
notice):

 

Greenberg Traurig, LLP

MetLife Building

200 Park Avenue

New York, New York 10166

Attention: Alan Annex; Kevin Friedmann; Jason Simon

Email: AnnexA@gtlaw.com; FriedmannK@gtlaw.com; SimonJ@gtlaw.com

 

o. THIS SUBSCRIPTION
AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAWS THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE.

 

    17

     

    

 

THE PARTIES HERETO
IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, THE
SUPREME COURT OF THE STATE OF NEW YORK AND THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE STATE OF NEW YORK
SOLELY IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF THIS SUBSCRIPTION AGREEMENT AND THE DOCUMENTS REFERRED
TO IN THIS SUBSCRIPTION AGREEMENT AND IN RESPECT OF THE TRANSACTIONS CONTEMPLATED HEREBY, AND HEREBY WAIVE, AND AGREE NOT TO ASSERT,
AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT IS NOT SUBJECT
THERETO OR THAT SUCH ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE THEREOF
MAY NOT BE APPROPRIATE OR THAT THIS SUBSCRIPTION AGREEMENT OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND THE
PARTIES HERETO IRREVOCABLY AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED
BY SUCH A NEW YORK STATE OR FEDERAL COURT. THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT JURISDICTION OVER THE PERSON
OF SUCH PARTIES AND OVER THE SUBJECT MATTER OF SUCH DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH
SUCH ACTION, SUIT OR PROCEEDING IN THE MANNER PROVIDED IN SECTION 11(n) OR IN SUCH OTHER MANNER AS MAY BE PERMITTED BY LAW SHALL
BE VALID AND SUFFICIENT SERVICE THEREOF.

 

EACH PARTY ACKNOWLEDGES
AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY IS LIKELY
TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT
SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THE FOREGOING
WAIVER; (III) SUCH PARTY MAKES THE FOREGOING WAIVER VOLUNTARILY AND (IV) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS SUBSCRIPTION
AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 11(o).

 

[SIGNATURE PAGES
FOLLOW]

 

    18

     

    

 

IN WITNESS WHEREOF,
the undersigned has executed or caused this Subscription Agreement to be executed by its duly authorized representative as of the
date set forth below.

 

	Name of Investor:	 	State/Country of Formation or Domicile:
	 	 	 
	By:	                       	 	 
	Name: 	 	 	 
	Title:	 	 	 
	 	 	 
	Name in which shares are to be registered (if different):	 	Date: _______________, 2020
	Investor’s EIN:	 	 
	 	 	 
	Business Address-Street:	 	Mailing Address-Street (if different):
	 	 	 
	City, State, Zip:	 	City, State, Zip:
	 	 	 
	Attn:	 	 	Attn:	                
	 	 	 
	Telephone No.:	 	Telephone No.:
	Facsimile No.:	 	Facsimile No.:
	Email Address:	 	Email Address:
	 	 	 
	Number of Shares subscribed for:	 	 
	 	 	 
	Aggregate Subscription Amount: $	 	Price Per Share: $10.00

 

The above Subscriber
agrees that it shall pay the Purchase Price by wire transfer of United States dollars in immediately available funds to the account
specified by the Company in the Closing Notice.

 

    19

     

    

 

IN WITNESS WHEREOF,
InterPrivate Acquisition Corp. has accepted this Subscription Agreement as of the date set forth below.

 

	 	INTERPRIVATE ACQUISITION CORP.
	 	 
	 	By:	 
	 	Name: 	                       
	 	Title:	 

 

Date: ____________, 2020

 

    20

     

    

 

SCHEDULE A

ELIGIBILITY REPRESENTATIONS OF THE INVESTOR

 

		A.	QUALIFIED INSTITUTIONAL BUYER STATUS

 

(Please check the applicable
subparagraphs):

 

	 	1.	☐	We are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act).

 

		B.	INSTITUTIONAL ACCREDITED INVESTOR STATUS

 

(Please check the applicable
subparagraphs):

 

	 	1.	☐	We are an “accredited investor” (within the meaning of Rule 501(a) under the Securities Act. for one or more of the following reasons (Please check the applicable subparagraphs):

 

	 	☐	We are a bank, as defined in Section 3(a)(2) of the Securities Act or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act, whether acting in an individual or a fiduciary capacity.
	 	 	 
	 	☐	We are a broker or dealer registered under Section 15 of the Securities Exchange Act of 1934, as amended.
	 	 	 
	 	☐	We are an insurance company, as defined in Section 2(13) of the Securities Act.
	 	 	 
	 	☐	We are an investment company registered under the Investment Company Act of 1940 or a business development company, as defined in Section 2(a)(48) of that act.
	 	 	 
	 	☐	We are a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958.
	 	 	 
	 	☐	We are a plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if the plan has total assets in excess of $5 million.
	 	 	 
	 	☐	We are an employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, if the investment decision is being made by a plan fiduciary, as defined in Section 3(21) of such act, and the plan fiduciary is either a bank, an insurance company, or a registered investment adviser, or if the employee benefit plan has total assets in excess of $5 million.
	 	 	 
	 	☐	We are a private business development company, as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.

 

    Schedule A

     

    

 

	 	☐	We are a corporation, Massachusetts or similar business trust, or partnership, or an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, that was not formed for the specific purpose of acquiring the Securities, and that has total assets in excess of $5 million.
	 	 	 
	 	☐	We are a trust with total assets in excess of $5 million not formed for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) under the Securities Act.
	 	 	 
	 	☐	We are an entity in which all of the equity owners are accredited investors.

 

		C.	AFFILIATE STATUS

 

(Please check the applicable
box)

 

THE INVESTOR:

 

		☐	is:

 

		☐	is not:

 

an “affiliate” (as
defined in Rule 144 under the Securities Act) of the Company or acting on behalf of an affiliate of the Company.

 

This page should
be completed by the Investor and constitutes a part of the Subscription Agreement

 

    Schedule A

     

    

 

SCHEDULE B

ELIGIBILITY REPRESENTATIONS OF THE INVESTOR
(Canadian Investors Only)

 

		1.	We hereby declare, represent and warrant that:

 

		(a)	we are purchasing the Shares as principal for our own account, or are deemed to be purchasing the
Shares as principal for our own account in accordance with applicable Canadian securities laws, and not as agent for the benefit
of another investor;

 

		(b)	we are residents in or subject to the laws of one of the provinces or territories of Canada;

 

		(c)	we are entitled under applicable securities laws to purchase the Shares without the benefit of
a prospectus qualified under such securities laws and, without limiting the generality of the foregoing, are both:

 

		a.	an “accredited investor” as defined in section 1.1 of National Instrument 45-106 Prospectus
Exemptions (“NI 45-106”) or section 73.3(2) of the Securities Act (Ontario) by virtue of satisfying the
indicated criterion in Section 11 below, and we are not a person created or used solely to purchase or hold securities as an “accredited
investor” as described in paragraph (m) of the definition of “accredited investor” in section 1.1 of NI 45-106;
and

 

		b.	a “permitted client” as defined in section 1.1 of National Instrument 31-103 Registration
Requirements, Exemptions and Ongoing Registrant Obligations (“NI 31-103”) by virtue of satisfying the indicated
criterion in Section 12 below

 

		(d)	we have received, reviewed and understood, this Subscription Agreement and certain disclosure materials
relating to the placing of Shares in Canada and, are basing our investment decision solely on this Subscription and the materials
provided by the Company and not on any other information concerning the Company or the offering of the Shares;

 

		(e)	the acquisition of Shares does not and will not contravene any applicable Canadian securities laws,
rules or policies of the jurisdiction in which we are resident and does not trigger (i) any obligation to prepare and file a prospectus
or similar document or (ii) any registration or other similar obligation on the part of any person;

 

		(f)	we will execute and deliver within the applicable time periods all documentation as may be required
by applicable Canadian securities laws to permit the purchase of the Shares on the terms set forth herein and, if required by applicable
Canadian securities laws, will execute, deliver and file or assist the Company in obtaining and filing such reports, undertakings
and other documents relating to the purchase of the Shares as may be required by any applicable Canadian securities laws, securities
regulator, stock exchange or other regulatory authority; and

 

		(g)	neither we nor any party on whose behalf we are acting has been established, formed or incorporated
solely to acquire or permit the purchase of Shares without a prospectus in reliance on an exemption from the prospectus requirements
of applicable Canadian securities laws.

 

    Schedule B

     

    

 

		2.	We are aware of the characteristics of the Shares, the risks relating to an investment therein
and agree that we must bear the economic risk of its investment in the Shares. We understand that we will not be able to resell
the Shares under applicable Canadian securities laws except in accordance with limited exemptions and compliance with other requirements
of applicable law, and we (and not the Company) are responsible for compliance with applicable resale restrictions or hold periods
and will comply with all relevant Canadian securities laws in connection with any resale of the Shares.

 

		3.	We hereby undertake to notify the Company immediately of any change to any declaration, representation,
warranty or other information relating to us set forth herein which takes place prior to the closing of the purchase of the Shares
applied for hereby.

 

		4.	We understand and acknowledge that (i) the Company is not a reporting issuer in any province or
territory in Canada and its securities are not listed on any stock exchange in Canada and there is currently no public market for
the Shares in Canada; and (ii) the Company currently has no intention of becoming a reporting issuer in Canada and the Company
is not obligated to file and has no present intention of filing a prospectus with any securities regulatory authority in Canada
to qualify the resale of the Shares to the public, or listing the Company’s securities on any stock exchange in Canada and
thus the applicable restricted period or hold period may not commence and the Shares may be subject to an unlimited hold period
or restricted period in Canada and in that case may only be sold pursuant to limited exemptions under applicable securities legislation.

 

		5.	We confirm we have reviewed applicable resale restrictions under relevant Canadian legislation
and regulations.

 

		6.	It is acknowledged that we should consult our own legal and tax advisors with respect to the tax
consequences of an investment in the Shares in our particular circumstances and with respect to the eligibility of the Shares for
investment by us and resale restrictions under relevant Canadian legislation and regulations, and that we have not relied on the
Company or on the contents of the disclosure materials provided by the Company, for any legal, tax or financial advice.

 

		7.	If we are a resident of Quebec, we acknowledge that it is our express wish that all documents evidencing
or relating in any way to the sale of the Shares be drawn in the English language only. Si nous sommes résidents de la
province de Québec, nous reconnaissons par les présentes que c’est notre volonté expresse que tous les
documents faisant foi ou se rapportant de quelque manière à la vente des engagements soient rédigés
en anglais seulement.

 

		8.	We understand and acknowledge that we are making the representations, warranties and agreements
contained herein with the intent that they may be relied upon by the Company and the agents in determining our eligibility to purchase
the Shares, including the availability of exemptions from the prospectus requirements of applicable Canadian securities laws in
connection with the issuance of the Shares.

 

		9.	We consent to the collection, use and disclosure of certain personal information for the purposes
of meeting legal, regulatory, self-regulatory, security and audit requirements (including any applicable tax, securities, money
laundering or anti-terrorism legislation, rules or regulations) and as otherwise permitted or required by law, which disclosures
may include disclosures to tax, securities or other regulatory or self-regulatory authorities in Canada and/or in foreign jurisdictions,
if applicable, in connection with the regulatory oversight mandate of such authorities.

 

    Schedule B

     

    

 

		10.	If we are an individual resident in Canada, we acknowledge that: (A) the Company or the agents
may be required to provide personal information pertaining to us as required to be disclosed in Schedule I of Form 45-106F1
Report of Exempt Distribution (“Form 45-106F1”) under NI 45-106 (including its name, email address, address, telephone
number and the aggregate purchase price paid by the purchaser) (“personal information”) to the securities regulatory
authority or regulator in the local jurisdiction (the “Regulator”); (B) the personal information is being collected
indirectly by the Regulator under the authority granted to it in securities legislation; and (C) the personal information is being
collected for the purposes of the administration and enforcement of the securities legislation; and by purchasing the securities,
we shall be deemed to have authorized such indirect collection of personal information by the Regulator. Questions about the indirect
collection of information should be directed to the Regulator in the local jurisdiction, using the contact information set out
below:

 

		(a)	in Alberta, the Alberta Securities Commission, Suite 600, 250 - 5th Street SW, Calgary, Alberta
T2P 0R4, Telephone: (403) 297-6454, toll free in Canada: 1-877-355-0585;

 

		(b)	in British Columbia, the British Columbia Securities Commission, P.O. Box 10142, Pacific Centre,
701 West Georgia Street, Vancouver, British Columbia V7Y 1L2, Inquiries: (604) 899-6581, toll free in Canada: 1-800-373-6393, Email:
inquiries@bcsc.bc.ca;

 

		(c)	in Manitoba, The Manitoba Securities Commission, 500 - 400 St. Mary Avenue, Winnipeg, Manitoba
R3C 4K5, Telephone: (204) 945-2548, toll free in Manitoba 1-800-655-5244;

 

		(d)	in New Brunswick, Financial and Consumer Services Commission (New Brunswick), 85 Charlotte Street,
Suite 300, Saint John, New Brunswick E2L 2J2, Telephone: (506) 658-3060, toll free in Canada: 1-866-933-2222, Email: info@fcnb.ca;

 

		(e)	in Newfoundland and Labrador, Government of Newfoundland and Labrador, Financial Services Regulation
Division, P.O. Box 8700, Confederation Building, 2nd Floor, West Block, Prince Philip Drive, St. John’s, Newfoundland and
Labrador, A1B 4J6, Attention: Director of Securities, Telephone: (709) 729-4189,

 

		(f)	in the Northwest Territories, the Government of the Northwest Territories, Office of the Superintendent
of Securities, P.O. Box 1320, Yellowknife, Northwest Territories X1A 2L9, Attention: Deputy Superintendent, Legal & Enforcement,
Telephone: (867) 920-8984;

 

		(g)	in Nova Scotia, the Nova Scotia Securities Commission, Suite 400, 5251 Duke Street, Duke Tower,
P.O. Box 458, Halifax, Nova Scotia B3J 2P8, Telephone: (902) 424-7768;

 

		(h)	in Nunavut, Government of Nunavut, Department of Justice, Legal Registries Division, P.O. Box 1000,
Station 570, 1st Floor, Brown Building, Iqaluit, Nunavut X0A 0H0, Telephone: (867) 975-6590;

 

		(i)	in Ontario, the Inquiries Officer at the Ontario Securities Commission, 20 Queen Street West, 22nd
Floor, Toronto, Ontario M5H 3S8, Telephone: (416) 593-8314, toll free in Canada: 1-877-785-1555, Email: exemptmarketfilings@osc.gov.on.ca;

 

		(j)	in Prince Edward Island, the Prince Edward Island Securities Office, 95 Rochford Street, 4th Floor
Shaw Building, P.O. Box 2000, Charlottetown, Prince Edward Island C1A 7N8, Telephone: (902) 368-4569;

 

    Schedule B

     

    

 

		(k)	in Québec, the Autorité des marchés financiers, 800, Square Victoria, 22e
étage, C.P. 246, Tour de la Bourse, Montréal, Québec H4Z 1G3, Telephone: (514) 395-0337 or 1-877-525-0337,
Email: financementdessocietes@lautorite.qc.ca (For corporate finance issuers), fonds_dinvestissement@lautorite.qc.ca (For investment
fund issuers);

 

		(l)	in Saskatchewan, the Financial and Consumer Affairs Authority of Saskatchewan, Suite 601 - 1919
Saskatchewan Drive, Regina, Saskatchewan S4P 4H2, Telephone: (306) 787-5879; and

 

		(m)	in Yukon, Government of Yukon, Department of Community Services, Law Centre, 3rd Floor, 2130 Second
Avenue, Whitehorse, Yukon Y1A 5H6, Telephone: (867) 667-5314.

 

		11.	We hereby represent, warrant, covenant and certify that we are, or any party on whose behalf we
are acting is, an “accredited investor” as defined in NI 45-106 or section 73.3(1) of the Securities Act (Ontario)
by virtue of satisfying the indicated criterion below:

 

Please check the category
that applies:

 

	☐	 	a Canadian financial institution or a Schedule III bank of the Bank Act (Canada),
	☐	 	the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada),
	☐	 	a subsidiary of any person or company referred to in paragraphs (a) or (b) if the person or company owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary,
	☐	 	a person or company registered under the securities legislation of a province or territory of Canada as an adviser or dealer, except as otherwise prescribed by the regulations,
	 	 	[omitted]
	 	(e.1)	[omitted]
	☐	 	the Government of Canada, the government of a province or territory of Canada, or any Crown corporation, agency or wholly owned entity of the Government of Canada or of the government of a province or territory of Canada,
	☐	 	a municipality, public board or commission in Canada and a metropolitan community, school board, the Comité de gestion de la taxe scolaire de l’île de Montréal or an intermunicipal management board in Québec,
	☐	 	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that government,
	☐	(i)	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a province or territory of Canada,
	 	 	[omitted]
	☐	(j.1)	an individual who beneficially owns financial assets having an aggregate realizable value that before taxes, but net of any related liabilities, exceeds CAD$5,000,000,
	 	 	[omitted]
	 	 	[omitted]
	☐	 	a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared financial statements,

 

    Schedule B

     

    

 

	☐	 	an investment fund that distributes or has distributed its securities only to
	 	 	a person that is or was an accredited investor at the time of the distribution,
	 	 	a person that acquires or acquired securities in the circumstances referred to in sections 2.10 of NI 45-106 [Minimum amount investment], or 2.19 of NI 45-106 [Additional investment in investment funds], or
	 	 	a person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 of NI 45-106 [Investment fund reinvestment],
	☐	 	an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator or, in Québec, the securities regulatory authority, has issued a receipt,
	☐	 	a trust company or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust company or trust corporation, as the case may be,
	☐	 	a person acting on behalf of a fully managed account1 managed by that person, if that person is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction,
	☐	 	a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities being traded,
	☐	 	an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) through (d) or paragraph (i) in form and function,
	☐	 	a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited investors,
	☐	 	an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser,
	☐	 	a person that is recognized or designated by the Commission as an accredited investor,
	☐	 	a trust established by an accredited investor for the benefit of the accredited investor’s family members of which a majority of the trustees are accredited investors and all of the beneficiaries are the accredited investor’s spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited investor, of that accredited investor’s spouse or of that accredited investor’s former spouse.

 

		12.	We hereby represent, warrant, covenant and certify that we are, or any party on whose behalf we
are acting is, a “permitted client” by virtue of the criterion indicated below,

 

Please check the category
that applies:

 

	 	q	(a)	a Canadian financial institution or a Schedule III bank;

 

 

		1	A “fully managed account” means an account of a client for which a person makes the investment decisions
if that person has full discretion to trade in securities for the account without requiring the client’s express consent
to a transaction.

 

    Schedule B

     

    

 

	 	q	(b)	the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada);
	 	q	(c)	a subsidiary of any person or company referred to in paragraph (a) or (b), if the person or company owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of the subsidiary;
	 	q	(d)	a person or company registered under the securities legislation of a jurisdiction of Canada as an adviser, investment dealer, mutual fund dealer or exempt market dealer;
	 	q	(e)	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions or a pension commission or similar regulatory authority of a jurisdiction of Canada or a wholly-owned subsidiary of such a pension fund;
	 	q	(f)	an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) through (e);
	 	q	(g)	the Government of Canada or a jurisdiction of Canada, or any Crown corporation, agency or wholly-owned entity of the Government of Canada or a jurisdiction of Canada;
	 	q	(h)	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that government;
	 	q	(i)	a municipality, public board or commission in Canada and a metropolitan community, school board, the Comité de gestion de la taxe scolaire de l’île de Montréal or an intermunicipal management board in Quebec;
	 	q	(j)	a trust company or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a managed account managed by the trust company or trust corporation, as the case may be;
	 	q	(k)	a person or company acting on behalf of a managed account managed by person or company, if the person or company is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction;
	 	q	(l)	
        an investment fund if one or both of the
        following apply:

        (i) the fund is managed by a person or
        company registered as an investment fund manager under the securities legislation of a jurisdiction of Canada;

        (ii) the fund is advised by a person or
        company authorized to act as an adviser under the securities legislation of a jurisdiction of Canada;

	 	q	(m)	in respect of a dealer, a registered charity under the Income Tax Act (Canada) that obtains advice on the securities to be traded from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity;
	 	q	(n)	in respect of an adviser, a registered charity under the Income Tax Act (Canada) that is advised by an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity;
	 	q	(o)	a registered charity under the Income Tax Act (Canada) that obtains advice on the securities to be traded from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity;

 

    Schedule B

     

    

 

	 	q	(p)	an individual who beneficially owns financial assets having an aggregate realizable value that, before taxes but net of any related liabilities, exceeds $5 million;
	 	q	(q)	a person or company that is entirely owned by an individual or individuals referred to in paragraph (o), who holds the beneficial ownership interest in the person or company directly or through a trust, the trustee of which is a trust company or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction;
	 	q	(r)	a person or company, other than an individual or an investment fund, that has net assets of at least C$25,000,000 as shown on its most recently prepared financial statements; or
	 	q	(s)	a person or company that distributes securities of its own issue in Canada only to persons or companies referred to in paragraphs (a) through (r).

 

 

Schedule B​

Exhibit 10.7
​
CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT
​
This Consent and Third Amendment to Amended and Restated Credit Agreement (herein, this “Amendment”) is entered into as of July 9, 2020 (the “Third Amendment Effective Date”), among GLOBAL MEDICAL REIT L.P., a Delaware limited partnership (the “Borrower”), GLOBAL MEDICAL REIT INC., a Maryland corporation (the “Parent” or “Global Medical REIT”), as a Guarantor, the other Guarantors party hereto, the Lenders party hereto, and BMO HARRIS BANK N.A., as Administrative Agent (in such capacity, the “Administrative Agent”).
​
PRELIMINARY STATEMENTS
​
A.Borrower, Parent, the other Guarantors party thereto, the Lenders party thereto, and the Administrative Agent have heretofore entered into that certain Amended and Restated Credit Agreement, dated as of August 7, 2018, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of September 30, 2019 and the Second Amendment to Amended and Restated Credit Agreement dated as of October 12, 2019 (such Credit Agreement, as amended, restated, supplemented or otherwise modified from time to time, being referred to herein as the “Credit Agreement”). All capitalized terms used herein without definition shall have the same meanings herein as such terms have in the Credit Agreement, as amended by this Amendment.
​
B.Borrower has requested that (i) the Lenders consent to the Internalization Acquisition (as hereinafter defined) and the Internalization (as hereinafter defined), and (ii) certain other changes be made to the Credit Agreement, and Administrative Agent and the Lenders are willing to do so pursuant to the terms below.
​
C.This Amendment shall constitute a Loan Document and these Preliminary Statements shall be construed as part of this Amendment.
​
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
​
SECTION 1.CONSENT TO INTERNALIZATION ACQUISITION AND INTERNALIZATION.
​
The Borrower has informed the Administrative Agent that (i) Global Medical REIT intends to consummate the Internalization Acquisition pursuant to the Internalization Acquisition Agreement on or about the Third Amendment Effective Date, and (ii) pursuant to the Internalization, Global Medical REIT intends to internalize all of the services provided to it by the Manager (as hereinafter defined). As a result, the Borrower has requested that the Administrative Agent and the Required Lenders consent to the Internalization Acquisition and the Internalization. By their execution of this Amendment and upon satisfaction of the  conditions precedent set forth in Section 4 below, Administrative Agent and the Required Lenders acknowledge the satisfaction of the conditions precedent set forth in Section 4 below, and the Administrative Agent and the Required Lenders hereby consent to the Internalization Acquisition and the Internalization subject to the terms and conditions herein.
​
​
​

​

​

SECTION 2.AMENDMENT TO CREDIT AGREEMENT.
​
Subject to the satisfaction of the conditions precedent set forth in Section 4 below, the Credit Agreement is hereby amended as follows:
​
2.1.Section 1.1 (Commitments) of the Credit Agreement is hereby amended by inserting a new Section 1.1(c) in its appropriate alphabetical order to read as follows:
​
(c)Notwithstanding anything to the contrary in this Agreement, subject to the terms and conditions set forth in this Agreement, each of the Lenders severally agrees to lend to Global Medical REIT upon notice by Global Medical REIT to the Administrative Agent given in accordance with Section 1.6 (with references to the Borrower deemed for purposes hereof to refer to Global Medical REIT), an amount not greater than Twenty-Five Million Dollars ($25,000,000) (the “Global Medical REIT Loan”) through one or more advances made on or before September 9, 2020. The principal amount of the Global Medical REIT Loan shall constitute usage of the Revolving Credit Commitment. The Global Medical REIT Loan shall be made pro rata in accordance with each Lender’s Revolver Percentage. Each request with  respect to the Global Medical REIT Loan hereunder shall constitute a representation and warranty by Global Medical REIT (and, for the sake of clarity, not the Borrower) that all of the conditions required of Global Medical REIT set forth in Section 7.1 have been satisfied on  the date of such request. The Administrative Agent may assume that the conditions in Section 7 have been satisfied unless it receives prior written notice from a Lender that such conditions have not been satisfied. No amount repaid or prepaid on the Global Medical REIT Loan may be borrowed again by Global Medical REIT (but, for the sake of clarity, such repayments or prepayments shall not constitute a commitment reduction of the Revolving Credit Commitment and may be reborrowed by the Borrower subject to the terms and conditions hereof). Global Medical REIT (and, for the sake of clarity, not the Borrower) promises to pay interest on the Global Medical REIT Loan in arrears on each Interest Payment Date with respect thereto at the same interest rate and otherwise on the same terms as provided in the Loan Documents for other Borrowings under the Revolving Credit Commitment. Upon receipt by the Administrative Agent from each Lender of such Lender’s Revolver Percentage of the amount of the requested Global Medical REIT Loan and the satisfaction of the conditions set forth in Section 7.1 hereof, the Administrative Agent will make available to Global Medical REIT the aggregate amount of the Global Medical REIT Loan  as  instructed  by  Global  Medical  REIT.    Global  Medical
​
​

-2-

​

REIT will use the proceeds of the Global Medical REIT Loan solely for (a) the consummation of the Internalization and Internalization Acquisition, (b) payment of costs and expenses in connection with the Internalization Acquisition, and (c) anticipated post-closing working capital and other adjustments, and costs expected to be incurred to carry the Global Medical REIT Loan, in each case to the extent not prohibited by applicable law or by the organizational documents of Global Medical REIT. Global Medical REIT promises to pay on the Termination Date and there shall become absolutely due and payable on the Termination Date all of the Global Medical REIT Loan outstanding on such date, together with any and all accrued and unpaid interest thereon. Notwithstanding anything to the contrary in this Agreement, Sections 1, 3, 5, 9.1(a), 9.2, 9.3, 9.4, 10, 11 and 12 of this Agreement shall be applicable to Global Medical REIT, with references to the Borrower deemed for purposes hereof to refer to Global Medical REIT. Except as expressly provided in the foregoing sentence, all other Sections of this Agreement shall not apply to Global Medical REIT as a borrower under the Global Medical REIT Loan; provided, that, as applicable, such Sections shall continue to apply to Global Medical REIT in its capacity as a Guarantor. Global Medical REIT represents and warrants to the Administrative Agent and the Lenders that: (i) the execution, delivery and performance of this Agreement and the other Loan Documents to which it is a party and the transactions contemplated hereby and thereby (a) are within the authority of Global Medical REIT, (b) have been duly authorized by all necessary proceedings on the part of Global Medical REIT, (c) do not and will not conflict with or result in any breach or contravention of any provision of any applicable Legal Requirement to which Global Medical REIT is subject, (d) do not and will not conflict with or constitute a default (whether with the passage of time or the giving of notice, or both) under any provision of the partnership agreement, articles of incorporation, declaration of trust or other charter documents or bylaws of Global Medical REIT, (e) do not and will not conflict with or result in any breach or contravention of any other agreement or other instrument binding upon, Global Medical REIT or any of its properties, where such contravention or default, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect, (f) do not and will not result in or require the imposition of any lien or other encumbrance on any of the properties, assets or rights of Global Medical REIT other than the liens and encumbrances in favor of the Administrative Agent contemplated by this Agreement and the other Loan Documents, and (g) do not require the approval or consent of any Person other than those already obtained and
​
​

-3-

​

delivered to the Administrative Agent; (ii) the execution and delivery of this Agreement and the other Loan Documents to which Global Medical REIT is a party are valid and legally  binding obligations of Global Medical REIT enforceable in accordance with the respective terms and provisions hereof and thereof, except as enforceability is limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other laws relating to or affecting generally the enforcement of creditors’ rights and general principles of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law); and (iii) the execution, delivery and performance of this Agreement and the other Loan Documents to which Global Medical REIT is a party and the transactions contemplated hereby and thereby do not require the approval or consent of, or filing or registration with, or the giving of any notice to, any court, department, board, governmental agency or authority other than those already obtained, and filings after the date hereof of disclosures with the SEC or as may be required hereafter with respect to tenant improvements, repairs or other work with respect to any Real Estate. Global Medical REIT covenants and agrees  that (i) it will duly and punctually pay or cause to be paid the principal and interest on the Global Medical REIT Loan and all interest and fees provided for with respect thereto in this Agreement, all in accordance with the terms of this Agreement and the Notes (all as if Global Medical REIT had been an original signatory thereto) for other Borrowings under the Revolving Credit Commitment, and (ii) it shall not, directly or indirectly, use the proceeds of the Global Medical REIT Loan or lend, contribute or otherwise make available such proceeds to any Guarantor, Subsidiary or other Person (x) to fund any activities or business of or with any Person, or in any country or territory, that at the time of such funding is itself the subject of territorial sanctions under applicable OFAC Sanctions Programs, (y) in any manner that would result in a violation of applicable OFAC Sanctions Programs or Anti-Corruption Laws by any Person (including any Person participating in the credit facilities hereunder, whether as underwriter, lender, advisor, investor, or otherwise), or (z) in any manner that would cause it, the Guarantors or any of their respective Subsidiaries to violate the FCPA. To remove all doubt and avoid any confusion, the parties agree that the Borrower shall not be a co-borrower with Global Medical REIT under the Global Medical REIT Loan, and Global Medical REIT shall not be a co- borrower with the Borrower for any of the other Obligations.
​
​
​

-4-

​

​
2.2.Section 1.8(b) (Prepayments, Mandatory) of the Credit Agreement is hereby amended by inserting a new clause (iii) in its appropriate numerical order to read as follows:
​
(iii) From and after the extension of the Global Medical REIT Loan, upon the occurrence of Global Medical REIT’s receipt of proceeds from any offering of Stock or Stock Equivalents of Global Medical REIT to any Person, the Borrower shall, within three (3) Business Days, and without notice or demand, pay to the Administrative Agent for the account of the Lenders the aggregate net proceeds received by Global Medical REIT with respect to such offering as and for a mandatory prepayment on the Obligations, with each such prepayment to be applied to the Global Medical REIT Loan until the Global Medical REIT Loan is paid in full.
​
2.3.Section 4.1 (Guaranties) of the Credit Agreement is hereby amended by (i) deleting the period at the end of that Section and (ii) inserting the below new phrase:
​
provided, however, that Global Medical REIT shall not guarantee its own Obligations, Hedging Liability, and Bank Product Obligations.
​
2.4.Section 5.1 (Definitions) of the Credit Agreement is hereby amended by inserting the following defined terms in appropriate alphabetical order to read as follows:
​
“Internalization” means the internalization by Global Medical REIT of the services provided to it by the Manager as more fully described in the Internalization Acquisition Agreement.
​
“Internalization Acquisition” means the purchase by Global Medical REIT from Jeff Busch and Zensun Enterprises Limited or its affiliates of all of the outstanding Equity Interests of Inter-American Group Holdings Inc. (“Inter-American Group Holdings”) pursuant to the Internalization Acquisition Agreement, for a purchase price (including working capital and other post- closing adjustments, if any) plus reasonable transaction and carrying costs and expenses related thereto not to exceed the Internalization Consideration, and the contribution to the Borrower by Global Medical REIT of certain Equity Interests of the Manager, such that following such purchase and contribution Borrower and its Subsidiaries will own 100% of the outstanding Equity Interests of the Manager.
​
“Internalization Acquisition Agreement” means that certain Stock Purchase Agreement dated as of July 9, 2020, between Global Medical REIT and Jeff Busch and Zensun Enterprises
​
​

-5-

​

Limited pursuant to which Global Medical REIT will acquire substantially all of the Equity Interests of Inter-American Group Holdings owned by Jeff Busch and Zensun Enterprises Limited or its affiliates on the Third Amendment Effective Date.
​
“Internalization Consideration” means the costs and expenses incurred by Global Medical REIT in connection with the Internalization; provided, however, that such Internalization Consideration shall not exceed $25,000,000.
​
“Management Agreement” means that certain Second Amended and Restated Asset Management Agreement dated as of July 9, 2020, by and among Global Medical REIT, the Borrower and the Manager, which Management Agreement is approved by Administrative Agent.
​
“Manager” means Inter-American Management, LLC, a Delaware limited liability company, or such successor entity approved by Administrative Agent.
​
2.5.Section 5.1 (Definitions) of the Credit Agreement is hereby further amended by amending and restating the following defined terms in their entirety to read as follows:
​
“Change of Control” means the occurrence of any of the following: (a) the acquisition by any “person” or “group” (as such terms are used in sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) at any time of beneficial ownership of more than 35% of the outstanding capital stock or other equity interests of Global Medical REIT entitled to vote for members of the board of directors or equivalent governing body of Global Medical REIT on a fully-diluted basis; (b) during any period of twelve (12) consecutive months, a majority of the members of the board of directors or other equivalent governing body of Global Medical REIT cease to be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, (ii) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body or (iii) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (i) and (ii) above constituting at the time of such election or nomination at least a majority of that board or
​
​

-6-

​

​
equivalent governing body, (c) the failure of Global Medical REIT to directly or indirectly (i) control the Borrower and (ii) own more than 51% of the total economic interest in the Equity Interests of the Borrower, or (d) the failure of Borrower to directly or indirectly (i) control the Manager and (ii) own more than 98% of the total economic interest in the Equity Interests of the Manager. A Person shall be deemed to control another Person for purposes  of this definition if such Person possesses, directly or indirectly, the power to direct, or cause the direction of, the management and policies of the other Person, whether through the ownership of voting securities, common directors, trustees or officers, by contract or otherwise.
​
“EBITDA” means, for any period, determined on a consolidated basis of Global Medical REIT and its Subsidiaries, in accordance with GAAP, the sum of net income (or loss) plus, to the extent included as an expense in the calculation of net income (or loss): (i) depreciation and amortization expense; (ii) Interest Expense; (iii) income tax expense; (iv) extraordinary, unrealized or non-recurring losses, including impairment charges and losses from the sale of assets and the Internalization Consideration to the extent incurred during the fiscal quarter ending September 30, 2020, in an amount not to exceed $25,000,000; (v) fees and expenses incurred in connection with dispositions, the incurrence of Indebtedness or the issuance of Capital Stock (whether or not consummated); and (vi) non-cash losses, (provided that any cash payment made with respect to any such non-cash loss shall be subtracted in computing EBITDA during the period in which such cash payment is made) minus: (a) extraordinary, unrealized or non-recurring gains, including the write-up of assets and gain from the sale of assets; (b) non-cash gains (provided that any receipt of cash in respect of such non-cash gains shall be added in computing EBITDA during the period in which such cash was received); and
(c) income tax benefits.
​
“Extension Fee” means an extension fee payable by the Borrower to the Administrative Agent for the ratable benefit of the Lenders as a condition to the extension of the Initial Termination Date pursuant to Section 1.16 hereto in an amount equal to 0.15% of the Revolving Credit Commitments then in effect.
​
“Loan” means (i) the Global Medical REIT Loan and (ii) any Revolving Loan, Swing Loan, Term Loan or Incremental Term Loan, whether outstanding as a Base Rate Loan or Eurodollar Loan or otherwise, each of which is a “type” of Loan hereunder. Notwithstanding the foregoing or anything else to the
​
​

-7-

​

contrary in this Agreement or any other Loan Document, as each may be amended, the inclusion of the Global Medical REIT Loan in the foregoing definition of "Loan" shall not be deemed to render (x) Borrower a co-borrower under or in any way liable for the repayment of the Global Medical REIT Loan, it being the parties' intention that the Global Medical REIT Loan is an independent obligation of Global Medical REIT, or (y) Global Medical REIT a co-borrower under any of the other Loans.
​
“Obligations” means all obligations of (i) Global Medical REIT to pay principal and interest on the Global Medical REIT Loan only and (ii) the Borrower to pay principal and interest on the Loans (excluding the Global Medical REIT Loan), all Reimbursement Obligations owing under the Applications, all fees and charges payable hereunder, and all other payment obligations of the Borrower or any Guarantor arising under or in relation to any Loan Document, in each case whether now existing or hereafter arising, due or to become due, direct or indirect, absolute or contingent, and howsoever evidenced, held or acquired. Notwithstanding the foregoing or anything else to the contrary in this Agreement or any other Loan Document, as each may be amended, the inclusion of the Global Medical REIT Loan in the foregoing definition of "Obligations" shall not be deemed to render (x) Borrower a co-borrower under or in any way liable for the repayment of the Global Medical REIT Loan, it being the parties' intention that the Global Medical REIT Loan is an independent obligation of Global Medical REIT, or (y) Global Medical REIT a co-borrower under any of the other Loans that evidence the Obligations, but it being further understood that all of the Collateral (including the Collateral owned by the Borrower) constitutes Collateral securing the Global Medical REIT Loan. Further, any reference in this Agreement or in any other Loan Document to Borrower’s payment of the Obligations or Obligations being payable by the Borrower shall be deemed to exclude any obligation of Borrower to pay the Global Medical REIT Loan and shall instead be deemed to refer to Global Medical REIT’s obligation to pay the Global Medical REIT Loan.
​
“Required Lenders” means, as of the date of determination thereof, (i) if there are fewer than three (3) unaffiliated Lenders, all Lenders and (ii) if there are three (3) or more unaffiliated Lenders, at least three (3) unaffiliated Lenders whose outstanding Loans, interests in Letters of Credit and Unused Revolving Credit Commitments constitute more than 50% of the sum of the total outstanding Loans, interests in Letters of Credit, and Unused Revolving Credit Commitments of the Lenders on such date. To
​
​

-8-

​

the extent provided in Section 12.13, the Loans, interests in Letters of Credit and Unused Revolving Credit Commitments of any Defaulting Lender shall be disregarded in determining Required Lenders at any time.
​
2.6.Section 6.4 (Use of Proceeds; Margin Stock) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:
​
The Borrower shall use the proceeds of the Term Loans, the Incremental Term Loans (if any) and the Revolving Credit solely to refinance existing Indebtedness, to fund acquisitions, to finance capital expenditures and/or working capital, for general corporate purposes and/or for payment of fees and expenses related to this Agreement. Global Medical REIT will use the proceeds of the Global Medical REIT Loan solely for (a) the consummation of the Internalization and Internalization Acquisition, (b) payment of costs and expenses in connection with the Internalization Acquisition, and (c) anticipated post-closing working capital and other adjustments, and costs expected to be incurred to carry the Global Medical REIT Loan, in each case to the extent not prohibited by applicable law or by the organizational documents of Global Medical REIT. None of Global Medical REIT, the Borrower nor any Guarantor is engaged in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulation U of the Board of Governors of the Federal Reserve System), and no part of the proceeds of any Loan or any other extension of credit made hereunder will be used to purchase or carry any such margin stock or to extend credit to others for the purpose of purchasing or carrying any such margin stock. Margin stock (as hereinabove defined) constitutes less than 25% of the assets of the Borrower and the Guarantors. The Borrower shall not use the proceeds of any Swing Loan to repay any previously-advanced Swing Loans.
​
2.7.Section 8.8 (Investments, Acquisitions, Loans and Advances) of the Credit Agreement is hereby amended by (i) deleting the “and” appearing at the end of clause (n), (ii) deleting the period at the end of clause (o) and replacing it with “; and” in lieu thereof, and (iii) inserting a new clause (p) in its appropriate alphabetical order to read as follows:
​
(p)the Internalization Acquisition.
​
2.8.Section 8.9 (Mergers, Consolidations and Sales) of the Credit Agreement is hereby amended by (i) deleting the “and” appearing at the end of clause (h), (ii) deleting the period at the end of clause (i) and replacing it with “; and” in lieu thereof, and (iii) inserting a new clause (j) in its appropriate alphabetical order to read as follows:
​
​

-9-

​

(j)the Internalization.
​
2.9.Section 8 (Covenants) of the Credit Agreement is hereby further amended by inserting a new Section 8.26 in its appropriate numerical order to read as follows:
​
Section 8.26.  Management Fees.  The   Borrower   shall not pay, and shall not permit any Guarantor to pay, any management fees or other payments under any management agreement to the Borrower or to any other manager that is an Affiliate of the Borrower or any other manager, in the event that a Default or an Event of Default shall have occurred and be continuing; provided, that notwithstanding any such Default or Event of Default, the Borrower and any Guarantor may continue to pay (i) management fees and other payments due to Manager under the Management Agreement or any successor management agreement approved by Administrative Agent and (ii) management fees and other payments to the Borrower or an Affiliate of the Borrower if such management fees and other payments do not exceed amounts paid or payable by the Borrower or such Affiliate to third-party managers engaged pursuant to a sub-management agreement to provide management services for the Borrower and/or its Affiliates.
​
2.10.The following sentence is added to the end of Section 9.1 of the Credit Agreement:
​
Notwithstanding anything herein to the contrary, all Loans and Obligations hereunder are cross-defaulted and an Event of Default with respect to any Loan shall result in an immediate Event of Default with respect to all Loans.
​
2.11.The first sentence of Section 13.1 (The Guarantees) of the Credit Agreement shall be amended and restated in its entirety to read as follows:
​
To induce the Lenders to provide the credits described herein and in consideration of benefits expected to accrue to the Borrower and Global Medical REIT by reason of the Commitments and for other good and valuable consideration, receipt of which is hereby acknowledged, each Guarantor party hereto (including any Material Subsidiary formed or acquired after the Closing Date executing a separate Guaranty or an Additional Guarantor Supplement in the form attached hereto as Exhibit G or such other form acceptable to the Administrative Agent) hereby unconditionally and irrevocably guarantees, jointly and severally, to the Administrative Agent, the Lenders, and their Affiliates, the due and punctual payment of all present and future Obligations,
​
​

-10-

​

Hedging Liability and Bank Product Obligations, including, but not limited to, the due and punctual payment of principal of and interest on the Loans, the Reimbursement Obligations, Hedging Liability, and Bank Product Obligations, and the due and punctual payment of all other obligations now or hereafter owed by the Borrower or Global Medical REIT under the Loan Documents as and when the same shall become due and payable, whether at stated maturity, by acceleration, or otherwise, according to the terms hereof and thereof (including all interest, costs, fees, and charges after the entry of an order for relief against the Borrower or such other obligor in a case under the United States Bankruptcy Code, the Canadian Bankruptcy Legislation or any similar proceeding, whether or not such interest, costs, fees and charges would be an allowed claim against the Borrower or any such obligor in any such proceeding); provided, however, that with respect to any Guarantor, its guarantee of Hedging Liability of the Borrower or any Guarantor shall exclude all Excluded Swap Obligations; provided further, that Global Medical REIT shall not guarantee its own Obligations, Hedging Liability, and Bank Product Obligations.
​
2.12.Exhibit E attached to the Credit Agreement shall be amended and restated in its entirety to read as set forth on Exhibit E attached hereto.
​
SECTION 3.REAFFIRMATION OF GUARANTIES.
​
Each Guarantor hereby (i) acknowledges and consents to the terms of this Amendment and the Credit Agreement as amended by this Amendment, (ii) confirms that its Guaranty in favor of the Administrative Agent, for the benefit of the Lenders, and all of its obligations thereunder, as amended, remain in full force and effect and (iii) reaffirms all of the terms, provisions, agreements and covenants contained in its Guaranty. Each Guarantor agrees that its consent to any further amendments or modifications to the Credit Agreement and other Loan Documents shall not be required solely as a result of this acknowledgment and consent having been obtained, except to the extent, if any, required by any Guaranty.
​
SECTION 4.CONDITIONS PRECEDENT.
​
The effectiveness of this Amendment is subject to the satisfaction of all of the following conditions precedent:
​
4.1.The Administrative Agent shall have received this Amendment duly executed by  the Borrower, each Guarantor, and the Required Lenders.
​
4.2.The Administrative Agent shall have received copies, certified as true and correct by a Responsible Officer of Borrower, of the Internalization Acquisition Agreement. All conditions precedent set forth in the Internalization Acquisition Agreement shall be satisfied in
​
​

-11-

​

all material respects (or waived) in accordance with the terms of the Internalization Acquisition Agreement, and each of the Internalization Acquisition Agreement shall not have been amended or otherwise modified, nor any term or provision thereof been waived (except in either case as disclosed to the Administrative Agent in writing), in a manner that would materially and adversely affect Borrower’s or any Guarantor’s ability to repay its Indebtedness, Obligations and liabilities to the Lenders under the Loan Documents or the financial condition of Borrower and the Guarantors taken as a whole. The Internalization Acquisition shall close substantially concurrently with the Third Amendment Effective Date.
​
4.3.The Administrative Agent shall have received copies, certified as true and correct by a Responsible Officer of Global Medical REIT, of the Management Agreement.
​
4.4.The Administrative Agent shall have received reasonably satisfactory evidence that there shall be no injunction, temporary restraining order or other legal action in effect which would prohibit the closing of the Internalization Acquisition or the transactions contemplated hereby.
​
4.5.Legal matters incident to the execution and delivery of this Amendment shall be reasonably satisfactory to the Administrative Agent and its counsel.
​
SECTION 5.REPRESENTATIONS.
​
In order to induce the Administrative Agent and the Lenders to execute and deliver this Amendment, the Borrower and each other Guarantor hereby represents to the Administrative Agent and the Lenders that (a) after giving effect to this Amendment, the representations and warranties set forth in Section 6 of the Credit Agreement, as amended by this Amendment, are and shall be and remain true and correct in all material respects as of the date hereof (or, if any such representation and warranty is expressly stated to have been made as of a specific date, as of such specific date) and (b) no Default or Event of Default has occurred and is continuing under the Credit Agreement or shall result after giving effect to this Amendment.
​
SECTION 6.MISCELLANEOUS.
​
6.1.Except as specifically amended herein, the Credit Agreement shall continue in full force and effect in accordance with its original terms. Reference to this specific Amendment need not be made in the Credit Agreement, the Notes, the other Loan Documents, or any other instrument or document executed in connection therewith, or in any certificate, letter or communication issued or made pursuant to or with respect to the Credit Agreement, any reference in any of such items to the Credit Agreement being sufficient to refer to the Credit Agreement as amended hereby. The Borrower and each Guarantor party hereto hereby, to the extent it granted liens on or security interests in any property pursuant to any Loan Documents, ratifies and reaffirms such grant of security and confirms that such liens and security interests continue to secure the obligations set forth therein and as amended hereby.
​
6.2.The Borrower agrees to pay on demand all reasonable costs and out-of-pocket expenses of or incurred by the Administrative Agent in connection with the negotiation,
​
​
​

-12-

​

preparation, execution and delivery of this Amendment, including the reasonable fees and out-of- pocket expenses of counsel for the Administrative Agent.
​
6.3.In order to induce the Administrative Agent and the Lenders to enter into this Amendment, Borrower and each Guarantor (collectively, the “Releasing Parties”) hereby absolutely and unconditionally releases and forever discharges the Administrative Agent, the L/C Issuer, and each Lender, and any and all participants, parent corporations, subsidiary corporations, affiliated corporations, insurers, indemnitors, successors and assigns thereof, together with all of the present and former directors, officers, agents, attorneys, consultants, representatives and employees of any of the foregoing (each a “Released Party”), from any and all claims, demands or causes of action of any kind, nature or description relating to or arising out of or in connection with or as a result of any of the Obligations, the Credit Agreement, and any other Loan Documents, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise, which each Releasing Party has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Agreement, whether such claims, demands and causes of action are matured or unmatured or known or unknown, other than, in each instance, as determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Released Party. Each Releasing Party acknowledges that it may hereafter discover facts different from or in addition to those now known or believed to be true with respect to such claims, demands, or causes of action and agree that this instrument shall be and remain effective in all respects notwithstanding any such differences or additional facts. Each Releasing Party understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.
​
6.4.This Amendment may be executed in any number of counterparts, and by the different parties on different counterpart signature pages, all of which taken together shall constitute one and the same agreement. Any of the parties hereto may execute this Amendment by signing any such counterpart and each of such counterparts shall for all purposes be deemed to be an original. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or in electronic (e.g., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Amendment. THIS AMENDMENT, AND THE RIGHTS AND DUTIES OF THE PARTIES HERETO, SHALL BE CONSTRUED AND DETERMINED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK (INCLUDING SECTION 5-1401 AND SECTION 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK) WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES THAT WOULD REQUIRE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION.
​
[SIGNATURE PAGES FOLLOW]
​
​

-13-

​

This Consent and Third Amendment to Amended and Restated Credit Agreement is entered into as of the date and year first above written.
​
	​

	​

	​

	​

	​
	BORROWERS:

	​
	​

	​
	GLOBAL MEDICAL REIT L.P.

	​
	​

	​
	By:
	GLOBAL MEDICAL REIT GP, LLC,

	​
	​
	a Delaware limited liability company,

	​
	​
	its General Partner

	​
	​

	​
	​
	By:
	GLOBAL MEDICAL REIT INC.,

	​
	​
	​
	a Maryland Corporation,

	​
	​
	​
	its Sole Member

	​
	​
	​
	​

	​
	​
	By:
	/s/ Robert Kiernan

	​
	​
	Name:
	Robert Kiernan

	​
	​
	Date:
	Treasurer and Chief Financial Officer

	​
	​
	​
	​

	​
	​

​
	​
	GLOBAL MEDICAL REIT INC., as Borrower for the

	​
	Global Medical REIT Loan

	​
	​

	​
	By
	/s/ Robert Kiernan

	​
	Name:
	Robert Kiernan

	​
	Title:
	Treasurer and Chief Financial Officer

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

​
	​

	​

	​

	​

	​
	GUARANTORS:

	​
	​

	​
	GLOBAL MEDICAL REIT INC.

	​
	​

	​
	By
	/s/ Robert Kiernan

	​
	Name:
	Robert Kiernan

	​
	Title:
	Treasurer and Chief Financial Officer

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

	GMR ALBERTVILLE, LLC
	GMR FORT WORTH, LLC
	GMR MORGANTOWN, LLC

	GMR ALTOONA, LLC
	GMR FREMONT, LLC
	GMR OKLAHOMA CITY, LLC

	GMR AMARILLO, LLC
	GMR GAINESVILLE, LLC
	GMR OKLAHOMA NORTHWEST, LLC

	GMR ASHEVILLE, LLC
	GMR GERMANTOWN, LLC
	GMR OMAHA, LLC

	GMR AURORA, LLC
	GMR GILBERT, LLC
	GMR ORLANDO, LLC

	GMR AUSTIN, LLC
	GMR GRAND RAPIDS BELTLINE, LLC
	GMR PANAMA CITY, LLC

	GMR BANNOCKBURN, LLC
	GMR GRAND RAPIDS WALKER, LLC
	GMR PANAMA CITY CHIPLEY, LLC

	GMR BASTROP, LLC
	GMR GRAND RAPIDS WILSON, LLC
	GMR PANAMA PCB, LLC

	GMR BEAUMONT, LLC
	GMR GREENWOOD, LLC
	GMR PRESCOTT, LLC

	GMR BELPRE, LLC
	GMR HIGH POINT, LLC
	GMR READING, LLC

	GMR BOUNTIFUL, LLC
	GMR JACKSONVILLE PONTE VEDRA, LLC
	GMR SAINT GEORGE, LLC

	GMR BROCKPORT, LLC
	GMR JACKSONVILLE RIVERSIDE, LLC
	GMR SAN MARCOS, LLC

	GMR CAPE CORAL, LLC
	GMR LANSING JOLLY 3390, LLC
	GMR SANDUSKY, LLC

	GMR CARSON CITY, LLC
	GMR LANSING JOLLY 3400, LLC
	GMR SHERMAN, LLC

	GMR CHANDLER DOBSON, LLC
	GMR LANSING JOLLY PATIENT, LLC
	GMR SOUTH BEND, LLC

	GMR CHANDLER PECOS I, LLC
	GMR LAS CRUCES, LLC
	GMR SOUTHERN IL, LLC

	GMR CHANDLER PECOS II, LLC
	GMR LAS VEGAS, LLC
	GMR SOUTHERN IL CARBONDALE, LLC

	GMR CHANDLER VAL VISTA I, LLC
	GMR LEE’S SUMMIT, LLC
	GMR SOUTHERN IL SHILOH 1191, LLC

	GMR CINCINNATI BEECHMONT, LLC
	GMR LEWISBURG, LLC
	GMR SOUTHERN IL SHILOH 1197, LLC

	GMR CLERMONT, LLC
	GMR LIVONIA, LLC
	GMR SURPRISE, LLC

	GMR CORONA, LLC
	GMR LUBBOCK, LLC
	GMR VERNON, LLC

	GMR EAST DALLAS HOSPITAL, LLC
	GMR MCALLEN, LLC
	GMR VERNON KEYNOTE, LLC

	GMR EAST DALLAS LAND, LLC
	GMR MECHANICSBURG, LLC
	GMR WATERTOWN, LLC

	GMR EAST ORANGE, LLC
	GMR MELBOURNE PINE, LLC
	GMR WEST ALLIS, LLC

	GMR ELLIJAY, LLC
	GMR MESA, LLC
	GMR WYOMISSING, LLC

	GMR FLOWER MOUND, LLC
	GMR MOLINE, LLC
	GMR ZACHARY, LLC

​
	​
	By:
	GLOBAL MEDICAL REIT L.P.,

	​
	​
	a Delaware limited partnership,

	​
	​
	its Sole Member

	​
	​
	​

	​
	​
	By:
	GLOBAL MEDICAL REIT GP, LLC,

	​
	​
	​
	a Delaware limited liability company,

	​
	​
	​
	its General Partner

	​
	​
	​
	​

	​
	​
	​
	By:
	GLOBAL MEDICAL REIT INC.,

	​
	​
	​
	​
	a Maryland Corporation,

	​
	​
	​
	​
	its Sole Member

	​
	​
	​
	​
	​

	​
	​
	​
	By:
	/s/ Robert Kiernan

	​
	​
	​
	Name:
	Robert Kiernan

	​
	​
	​
	Title:
	Treasurer and Chief Financial Officer

​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

	​
	ADMINISTRATIVE AGENT:

	​
	​

	​
	BMO HARRIS BANK N.A., as L/C Issuer and as

	​
	Administrative Agent

	​
	​

	​
	By:
	/s/ Michael Kauffman

	​
	​
	Name:
	Michael Kauffman

	​
	​
	Title:
	Managing Director

	​
	​
	​
	​

	​
	LENDERS:

	​
	​

	​
	BMO HARRIS BANK N.A., as a Lender

	​
	​

	​
	By:
	/s/ Michael Kauffman

	​
	​
	Name:
	Michael Kauffman

	​
	​
	Title:
	Managing Director

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

​
	K

	​

	​

	​

	​
	CITIZENS BANK, N.A.

	​
	​

	​
	By
	/s/ Frank Kaplan

	​
	​
	Name:
	Frank Kaplan

	​
	​
	Title:
	Vice President

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

​
	​

	​

	​

	​

	​
	TRUIST BANK (AS SUCCESSOR BY MERGER TO SUNTRUST BANK)

	​
	​

	​
	By
	/s/ Anton Brykalin

	​
	​
	Name
	Anton Brykalin

	​
	​
	Title
	Vice President

​
​

​

​

​
	​

	​

	​

	​

	​
	THE HUNTINGTON NATIONAL BANK

	​
	​

	​
	By
	/s/ Eva S. McQuillen

	​
	​
	Name
	Eva S. McQuillen

	​
	​
	Title
	Vice President

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

​
	​

	​

	​

	​

	​
	WELLS FARGO BANK, NATIONAL ASSOCIATION

	​
	​

	​
	By
	/s/ Darin Mullis

	​
	​
	Name
	Darin Mullis

	​
	​
	Title
	Managing Director

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

​
	​

	​

	​

	​

	​
	COMERICA BANK

	​
	​

	​
	By
	/s/ Casey L. Stevenson

	​
	​
	Name
	Casey L. Stevenson

	​
	​
	Title
	Vice President

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

​
	​

	​

	​

	​

	​
	KEYBANK NATIONAL ASSOCIATION

	​
	​

	​
	By
	/s/ Gregory W. Lane

	​
	​
	Name:
	Gregory W. Lane

	​
	​
	Title:
	Senior Vice President

​
​

[SIGNATURE PAGE TO CONSENT AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
(GLOBAL MEDICAL REIT L.P.)]

​

EXHIBIT E
​
COMPLIANCE CERTIFICATE
​
	​

	​

	To:
	BMO Harris  Bank  N.A.,  as  Administrative Agent under, and the Lenders party to, the Credit Agreement described below
	​

​
This Compliance Certificate is furnished to the Administrative Agent and the Lenders pursuant to that certain Amended and Restated Credit Agreement, dated as of August 7, 2018, among Global Medical REIT L.P., as Borrower, the Guarantors signatory thereto, the Administrative Agent and the Lenders party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Unless otherwise defined herein, the terms used in this Compliance Certificate have the meanings ascribed thereto in the Credit Agreement.
​
THE UNDERSIGNED HEREBY CERTIFIES THAT:
​
1.I am the duly elected ​ ​of Global Medical REIT L.P.;
​
2.I have reviewed the terms of the Credit Agreement and I have made, or have caused to be made under my supervision, a detailed review of the transactions and conditions of the Borrower and its Subsidiaries during the accounting period covered by the attached financial statements;
​
3.Except to the extent previously disclosed pursuant to the requirements of Section 8.5(e) of the Credit Agreement, the examinations described in paragraph 2 did not disclose, and I have no knowledge of, the existence of any condition or the occurrence of any event which constitutes a Default or Event of Default during or at the end of the accounting period covered by the attached financial statements or as of the date of this Compliance Certificate, except as set forth below;
​
4.The financial statements required by Section 8.5 of the Credit Agreement and being furnished to you concurrently with this Compliance Certificate are true, correct and complete in all material respects as of the date and for the periods covered thereby; and
​
5.The Schedule I hereto sets forth financial data and computations evidencing the Borrower’s compliance with certain covenants of the Credit Agreement, all of which data and computations are, to the best of my knowledge, true, complete and correct and have been made in accordance with the relevant Sections of the Credit Agreement.
​
Described below are the exceptions, if any, to paragraph 3 by listing, in detail, the nature of the condition or event, the period during which it has existed and the action which the Borrower has taken, is taking, or proposes to take with respect to each such condition or event:
​
​

​

​

​
The foregoing certifications, together with the computations set forth in Schedule I hereto and the financial statements delivered with this Certificate in support hereof, are made and delivered this          day of                  20    .
​
	​

	​

	​

	​

	​
	GLOBAL MEDICAL REIT L.P.

	​
	​

	​
	By:
	Global Medical REIT GP, LLC

	​
	Its:
	General Partner

	​
	​
	​

	​
	By:
	Global Medical REIT Inc.

	​
	Its: Sole Member

	​
	​
	​

	​
	By
	​

	​
	​
	Name
	​

	​
	​
	Title
	​

​
​

​

​

SCHEDULE I
TO COMPLIANCE CERTIFICATE

COMPLIANCE CALCULATIONS
FOR AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF AUGUST 7, 2018
CALCULATIONS AS OF ​ ​,​ ​

	​

	​

	​

	​

	A.
	Maximum Consolidated Leverage Ratio (Section 8.20(a))
	​

	​
	1.
	Total Indebtedness
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Ratio of Line A1 to Line A2
	      :1.0

	​
	4.
	Line A3 must not exceed
	0.65:1.01

	​
	​
	​
	0.60:1.02

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

	​
	​
	​
	​

	B.
	Minimum Fixed Charge Coverage Ratio (Section 8.20(b))
	​

	​
	1.
	Net income (or loss)
	$                        

	​
	2.
	Depreciation and amortization expense
	​

	​
	3.
	Interest Expense
	​

	​
	4.
	Income tax expense
	​

	​
	5.
	Extraordinary, unrealized, non-recurring or unusual losses, including impairment charges and the Internalization Consideration in an amount not to exceed $25,000,000
	​

	​
	6.
	Fees and expenses incurred in connection with dispositions, the incurrence of Indebtedness or the issuance of Capital Stock (whether or not consummated)
	​

	​
	7.
	Non-cash losses
	​

	​
	8.
	Sum of Lines B1 through B7
	​

	​
	9.
	Extraordinary, unrealized or non-recurring gains, including the write-up of assets
	​

1For each fiscal quarter ending on or before 09/30/2018-6/30/2019 
2For each fiscal quarter ending on 09/30/2019 and after
​

​

​

​
	​
	10.
	Non-cash gains
	​

	​
	11.
	Income tax benefits
	​

	​
	12.
	Sum of Lines B9, B10 and B11
	​

	​
	13.
	Line B8 minus Line B12 (“EBITDA”)
	​

	​
	14.
	EBITDA
	​

	​
	15.
	Acquisition expenses with respect to any Real Property
	​

	​
	16.
	Capital Reserve
	​

	​
	17.
	Line B14 plus Line B15 minus Line B16 and computed on an Annualized basis (“Adjusted EBITDA”)
	​

	​
	18.
	Interest Expense
	​

	​
	19.
	The greater of (i) zero or (ii) scheduled principal amortization paid on Total Indebtedness for such period (exclusive of any balloon payments or prepayments of principal paid on such Total Indebtedness)
	​

	​
	20.
	Line B18 plus Line B19 (“Debt Service”)
	​

	​
	21.
	Dividends and required distributions on Borrower’s preferred equity securities
	​

	​
	22.
	Income taxes paid
	​

	​
	23.
	Sum of Lines B20, B21 and B22 and computed on an Annualized Basis (“Fixed Charges”)
	​

	​
	24.
	Ratio of Line B14 to Line B23
	      :1.0

	​
	25.
	Line B24 shall not be less than
	1.50:1.0

	​
	26.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	C.
	Maintenance of Net Worth (Section 8.20(c))
	​

	​
	1.
	Net Worth as of [               ]
	$                        

	​
	2.
	Aggregate net proceeds received by Global Medical REIT or any of its Subsidiaries after March 31, 2018 in connection with any offering of Stock or Stock Equivalents
	​

	​
	3.
	75% of Line C2
	​

	​
	4.
	$203,795,000 plus Line C3
	​

	​
	5.
	Line C1 shall not be less than Line C4
	​

	​
	6.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
​

​

​

	​

	​

	​

	​

	D.
	Maximum Consolidated Secured Recourse Leverage Ratio (Section 8.20(d))
	​

	​
	1.
	Total Secured Recourse Indebtedness
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Ratio of Line D1 to Line D2
	      :1.0

	​
	4.
	Line D3 must not exceed
	0.10:1.0

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	E.
	Investments (Joint Ventures) (Section 8.8(o)(i))
	​

	​
	1.
	Cash investments in joint ventures
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Line E1 divided by Line E2
	​

	​
	4.
	Line E3 shall not exceed 10%
	​

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	F.
	Investments (Assets Under Development) (Section 8.8(o)(ii))
	​

	​
	1.
	Investments in Assets Under Development
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Line F1 divided by Line F2
	​

	​
	4.
	Line F3 shall not exceed 10%
	​

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	G.
	Investments (Land Assets) (Section 8.8(o)(iii))
	​

	​
	1.
	Investments in Land Assets
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Line G1 divided by Line G2
	​

	​
	4.
	Line G3 shall not exceed 5%
	​

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	H.
	Investments (mortgages and mezzanine loans) (Section 8.8(o)(iv))
	​

	​
	1.
	Investments in mortgages and mezzanine loans
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Line H1 divided by Line H2
	​

​
​

​

​

​
	​

	​

	​

	​

	​
	4.
	Line H3 shall not exceed 10%
	​

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	I.
	Other Investments (Section 8.8(o)(v))
	​

	​
	1.
	Other investments not otherwise permitted under the Credit Agreement
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Line I1 divided by Line I2
	​

	​
	4.
	Line I3 shall not exceed 5%
	​

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	J.
	Aggregate Investment Limitation to Total Asset Value (Section 8.8)
	​

	​
	1.
	Sum of Lines E1, F1, G1, H1 and II
	$                        

	​
	2.
	Total Asset Value as calculated on Exhibit A hereto
	​

	​
	3.
	Line J1 divided by Line J2
	​

	​
	4.
	Line J3 shall not exceed 20%
	​

	​
	5.
	The Borrower is in compliance (circle yes or no)
	yes/no

​
	​

	​

	​

	​

	K.
	Distributions to Adjusted FFO (Section 8.24(a))3
	​

	​
	1.
	Aggregate amount of cash distributions made by the Global Medical REIT to its equity holders
	$                        

	​
	2.
	Global Medical REIT’s Adjusted FFO
	​

	​
	3.
	95% of Line K2
	​

	​
	4.
	Amount necessary for Global Medical REIT to be able to make distributions required to maintain its status as a REIT and avoid the imposition of any federal or state income tax, and avoid the imposition of the tax described by Section 4981 of the Code
	​

	​
	5.
	Greater Line K3 and Line K4
	​

	​
	6.
	Line K1 shall not exceed Line K5
	​

	​
	7.
	The Borrower is in compliance (circle yes or no)
	yes/no

3Commencing with the fiscal quarter ending December 31, 2019.
​

​

​

EXHIBIT A TO SCHEDULE I 
TO COMPLIANCE CERTIFICATE 
OF GLOBAL MEDICAL REIT L.P.
​
This Exhibit A is attached to Schedule I to the Compliance Certificate of Global Medical REIT L.P. dated [                 ], 201    and delivered to BMO Harris Bank N.A., as Administrative Agent, and the Lenders party to the Credit Agreement referred to therein. The undersigned hereby certifies that the following is a true, correct and complete calculation of Total Asset Value as of the last day of the Fiscal Quarter most recently ended:
​
1. REAL PROPERTIES (OTHER THAN ASSETS UNDER DEVELOPMENT AND LAND ASSETS):
​
	PROPERTY
	GAAP BOOK VALUE (PLUS ALLOWANCE FOR ACCUMULATED DEPRECIATION)

	​
	​

	​
	​

	​
	​

	TOTAL:
	$                        

​
2. ASSETS UNDER DEVELOPMENT:
​
	PROPERTY
	GAAP BOOK VALUE OF ACTUAL FUNDED PORTION (PLUS ALLOWANCE FOR ACCUMULATED DEPRECIATION)

	​
	​

	​
	​

	​
	​

	TOTAL:
	$                        

​
3. LAND ASSETS
​
	PROPERTY
	GAAP BOOK VALUE

	​
	​

	​
	​

	​
	​

	TOTAL:
	$                        

​

​

​

54 OUTSTANDING PRINCIPAL BALANCE (OR SUCH LESSER AMOUNT REQUIRED BY GAAP) OF INVESTMENTS IN MORTGAGES AND OUTSTANDING PRINCIPAL BALANCE OF MEZZANINE LOANS EQUALS: $            .
​
TOTAL ASSET VALUE (SUM OF 1, 2, 3 AND 4) EQUALS: $ ​ ​.
​
	​

	​

	​

	​

	​
	GLOBAL MEDICAL REIT L.P.

	​
	​

	​
	By:
	Global Medical REIT GP, LLC

	​
	Its:
	General Partner

	​
	​

	​
	By:
	Global Medical REIT Inc.

	​
	Its: Sole Member

	​
	​

	​
	By
	​

	​
	​
	Name
	​

	​
	​
	Title
	​

​

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]